[November 07, 2008]

Rodman & Renshaw Annual Global Investment Conference Presenter Profiles

Company: 4SC AG
Ticker Symbol & Exchange: VSC / Xetra
Investor Relations Contact: Bettina von Klitzing
Investor Relations Contact
 Phone: 49-89-700 763 0
Web: www.4sc.com
Date of Presentation: November 10th, 2008
4SC AG develops innovative drug candidates against inflammatory
 diseases and cancer. 4SC AG utilises its proprietary technology
 platform, to create a sustainable project pipeline of drug
 candidates, which are to be developed up to clinical proof of
 concept in early clinical phases. There are currently eight projects
 in development. A clinical phase IIa for the treatment of rheumatoid
 arthritis has already successfully been completed. An additional
 project for the treatment of various cancers is currently completing
 a clinical phase I trial. The company is listed at the Prime
 Standard of Frankfurt Stock Exchange since December 2005.
Company: Aastrom Biosciences, Inc.
Ticker Symbol & Exchange: NASDAQ: ASTM
Investor Relations Contact: Kris M. Maly/Kimberli O'Meara
Investor Relations Contact
 Phone: (734) 930-5777
Web: www.aastrom.com
Date of Presentation: 11/11/2008; 5:20 PM-5:45 PM
Aastrom is a leader in the development of autologous cell products
 for the repair or regeneration of human tissue. Aastrom's Tissue
 Repair Cell (TRC) based products contain increased numbers of stem
 and early progenitor cells, produced from a small amount of bone
 marrow collected from the patient. The TRC technology platform has
 positioned Aastrom to advance multiple products into clinical
 development. The Company is currently focused on cardiovascular
 regeneration and is conducting a Phase II clinical trial with
 dilated cardiomyopathy (DCM) patients (the IMPACT-DCM trial) and a
 Phase IIb clinical trial with critical limb ischemia patients (the
 RESTORE-CLI trial).
Company: Access Pharmaceuticals, Inc.
Ticker Symbol & Exchange: ACCP.OB
Investor Relations Contact: Stephen B. Thompson
Investor Relations Contact
 Phone: 214-905-5100
Web: www.accesspharma.com
Date of Presentation: Tuesday, November 11, 2008
Access Pharmaceuticals, Inc. (ACCP.OB) is an emerging pharmaceutical
 company focused on the development and commercialization of
 proprietary products for the treatment and supportive care of cancer
 patients. Access has one approved product, MuGard(TM) for the
 management of oral mucositis that is partnered globally, and should
 commence sales in 4Q08. The company's lead oncology product is
 ProLindac(TM), a polymer-linked platinum cancer drug, which is in
 Phase 2 clinical testing in recurrent ovarian cancer patients.
 Angiolix(R) an antiangiogenic humanized monoclonal antibody, and
 Thiarabine, a novel nucleoside in trials in leukemia, are the
 company's lead oncology products. Access is also developing oral
 insulin and oral hGH using its proprietary Cobalamin(TM) oral drug
 delivery technology.
Company: Action Energy Inc.
Ticker Symbol & Exchange: AEC - TSX-V
Investor Relations Contact: Mr. Kelly D. Kerr - VP Finance
Investor Relations Contact
 Phone: (403) 723-4454
Web: www.action-energy.com
Date of Presentation: 11/10/2008
Action Energy Inc. is a Calgary Alberta based junior oil and natural
 gas exploration company focused on exploring the western Canadian
 sedimentary basin for properties with significant production and
 reserve potential. Action was incorporated in 2000 and to date has
 quickly grown to a company producing 1,500 - 1,600 boed through a
 combination of exploration and development drilling and mergers and
 acquisitions.
The Company has a portfolio mainly consisting of light oil properties
 focused on the Bakken and Midale plays in southeast Saskatchewan,
 heavy oil in the Lloydminster area of central Alberta and sweet
 natural gas properties in the Peace River Arch area of northwest
 Alberta. Action has captured large concentrated undeveloped land
 positions with high working interests in its primary plays giving
 the Company large upside potential.
Company: Active Biotech AB
Ticker Symbol & Exchange: ACTI; OMX Nordic
Investor Relations Contact: Mr Goran Forsberg
Investor Relations Contact
 Phone: +46 46 19 11 54
Web: www.activebiotech.com
Date of Presentation: 11/11/2008
Active Biotech AB (OMX NORDIC: ACTI), headquartered in Sweden, is a
 biotechnology company with R&D focus on autoimmune/inflammatory
 diseases and cancer. Projects in pivotal phase are laquinimod, an
 orally administered small molecule with unique immunomodulatory
 properties for the treatment of multiple sclerosis, as well as
 ANYARA for use in cancer targeted therapy, primarily renal cancer.
 Further key projects in clinical development comprise the three
 orally administered compounds TASQ for prostate cancer, 57-57 for
 SLE and RhuDex(R) for RA. Please visit www.activebiotech.com for
 more information.
Company: Acucela Inc.
Investor Relations Contact: Sayuri Refsland
Investor Relations Contact
 Phone: 425-527-3272
Web: www.acucela.com
Date of Presentation: 11/12/2008
Acucela Inc. is a clinical-stage biotechnology company focused on
 developing new drug therapies for blinding eye diseases such as age-
 related macular degeneration (AMD), Stargardt disease, diabetic
 retinopathy and retinopathy of prematurity, as well as dry eye. The
 most advanced product candidate of our developing compounds,
 Rebamipide ophthalmic suspension, is currently in Phase III clinical
 trials for dry eye and is being co-developed with Otsuka
 Pharmaceutical in the U.S. We are also conducting a Phase I clinical
 trial of ACU-4429 for dry age-related macular degeneration (AMD),
 which is also being co-developed with Otsuka Pharmaceutical.
Company: Adanac Molybdenum Corporation
Ticker Symbol & Exchange: AUA & Frankfurt A9N
Investor Relations Contact: Connie Fischer/Peter Jones
Investor Relations Contact 604.531.9639 or 604.535.6834
 Phone:
Web: www.adanacmoly.com
Date of Presentation: 11/11/2008
Adanac Molybdenum Corporation is listed on the TSX and Frankfurt
 exchanges and owns the Ruby Creek Molybdenum Project in Northern
 British Columbia. The Company has advanced the project through
 feasibility studies, a production decision and has previously
 ordered $137 million of long-lead equipment, completed permitting
 for construction, constructed a road to the site and secured US$80
 million in bridge financing. The Company is sourcing final
 construction funding and expects a site construction start in
 February 2009 and production in Q4, 2010. The mine will be the
 world's first new large scale molybdenum open pit mine in more than
 25 years.
Company: AgFeed Industries, Inc.
Ticker Symbol & Exchange: FEED (NASDAQ)
Investor Relations Contact: Mr. Gerry Daignault
Investor Relations Contact
 Phone: 615-480-7847
Web: www.agfeedinc.com
Date of Presentation: 11/10/2008 9:55 AM
AgFeed Industries, Inc. a US public company is the largest commercial
 hog producer and the largest premix feed company in China. With over
 600 million hogs produced each year, compared to 100 million in the
 US, China represents more than 50% of the world's annual hog
 production as well as the world's largest and most profitable pork
 consumer markets. We are a strategic platform for accessing China's
 vast feed and hog raising industries. The pre-mix feed market in
 which AgFeed operates is an approximately $1.6 billion segment of
 China's $40 billion per year animal feed market.
Company: Alberta Oilsands Inc.
Ticker Symbol & Exchange: AOS
Web: www.aboilsands.ca
Date of Presentation: November 12, 2008 at 10:20am
Alberta Oilsands Inc. (TSX-V: AOS) is a junior oil sands development
 company focused in the Athabasca oil sands region of northeast
 Alberta. The Company has acquired 89,920 gross (77,568 net) acres of
 prospective oil sands leases on the primary oil sands fairway.
AOS's strategy is to take advantage of its proven oil sands
 experience to delineate and prove up bitumen reserves sufficient to
 support a minimum 10,000 barrel per day in-situ project by 2012.
The company has four project areas, namely Clearwater, Hangingstone,
 Algar lake and Grand rapids which in aggregate hold nearly 5 billion
 barrels of bitumen in place. The Clearwater delineation drilling
 program in Q1-2009 provided the company with 320 million barrels of
 contingent recoverable bitumen resource over just 2800 acres and
 potentially two 10,000 barrels per day projects
Company: Alhambra Resources Ltd.
Ticker Symbol & Exchange: ALH - TSX Venture
Investor Relations Contact: Ihor P. Wasylkiw
Investor Relations Contact
 Phone: 1 (403) 508-4953
Web: www.alhambraresources.com
Date of Presentation: Tuesday, Nov 11/08 @ 2:50 PM EST
Alhambra is a Canadian based international exploration and gold
 production Corporation, celebrating its 7th year of operations in
 the Republic of Kazakhstan. Alhambra holds exploration and
 exploitation rights to a 2.7 million acre, 100% owned, property
 called the Uzboy Project, located in the prolific Charsk Gold Belt
 which hosts numerous world-class gold deposits. Alhambra is
 currently producing gold and has 14 years remaining of a 25 year
 license which is renewable for an additional 20 years and allows the
 Corporation to explore for all metals including gold, base metals,
 uranium and molybdenum.
Company: Allon Therapeutics Inc.
Ticker Symbol & Exchange: TSX:NPC
Investor Relations Contact: Aaron Keay
Investor Relations Contact Cell: (604) 323-6911, D: (604) 742-
 Phone: 2540
Web: www.allontherapeutics.com
Date of Presentation: Monday, November 10, 2008 - 9:30am
 ET
Allon Therapeutics Inc. is a clinical-stage biotechnology company
 focused on developing the first drugs that impact the progression of
 neurodegenerative diseases. Allon's lead clinical program is focused
 on Alzheimer's disease. In February 2008 the Company announced
 positive results in a Phase IIa clinical study for amnestic MCI, a
 precursor to Alzheimer's disease, showing statistically significant,
 dose dependant, and durable efficacy on human memory. The Company
 also has a Phase II trial underway in schizophrenia cognitive
 impairment.
The Company is listed on the Toronto Stock Exchange under the trading
 symbol "NPC" (Neuro Protection Company) and based in Vancouver.
Company: Allos Therapeutics, Inc.
Ticker Symbol & Exchange: NASDAQ: ALTH
Investor Relations Contact: Derek Cole
Investor Relations Contact
 Phone: 720.540.5367
Web: www.allos.com
Date of Presentation: Tuesday, November 11, 2008
Allos Therapeutics is a biopharmaceutical company focused on
 developing and commercializing small molecule therapeutics for the
 treatment of cancer. The Company's lead product candidate, PDX
 (pralatrexate), is a novel antifolate currently under evaluation in
 a pivotal Phase 2 (PROPEL) trial in patients with relapsed or
 refractory peripheral T-cell lymphoma. The Company expects to report
 top line results of the PROPEL trial by the end of 2008. The Company
 is also investigating PDX in patients with non-small cell lung
 cancer, bladder cancer and a range of lymphoma subtypes. The
 Company's other product candidate is RH1, a targeted
 chemotherapeutic agent currently being evaluated in a Phase 1 trial
 in patients with advanced solid tumors or non-Hodgkin's Lymphoma
 (NHL). Allos currently retains exclusive worldwide rights to PDX and
 RH1.
Company: Alphatec Spine
Ticker Symbol & Exchange: ATEC
Investor Relations Contact: Cheryl Monblatt
Investor Relations Contact
 Phone: 760 494 6746
Web: www.alphatecspine.com
Date of Presentation: Monday, November 10
Alphatec Spine is a medical device company that designs, develops,
 manufactures and markets products for the surgical treatment of
 spine disorders, primarily focused on the aging spine. The Company's
 mission is to combine world-class customer service with innovative,
 surgeon-driven design that will help improve the aging patient's
 quality of life. The Company is poised to achieve its goal through
 new solutions for patients with osteoporosis and other aging spine
 deformities, improved minimally invasive products and techniques and
 integrated biologics solutions. In addition to its U.S. operations,
 The Company also markets its spine products in Europe.
Company: Amarin Corporation
Ticker Symbol & Exchange: AMRN (Nasdaq)
Investor Relations Contact: Darren Cunningham
Investor Relations Contact
 Phone: 35316699020
Web: www.amarincorp.com
Date of Presentation: 11/11/08
Amarin is a clinical-stage biopharmaceutical company with a lead
 program entering Phase 3 for hypertriglyceridemia. Amarin's
 cardiovascular programs capitalize on its expertise in the field of
 lipid science and the known therapeutic benefits of essential fatty
 acids in cardiovascular disease.
Company: American Lorain Corporation
Ticker Symbol & Exchange: ALRC.OB
Investor Relations Contact: CCG Investor Relations
Investor Relations Contact Crocker Coulson, 646-213-1915
 Phone:
Web: www.lorainfood.com
Date of Presentation: November 10th at 3:15 pm ET
American Lorain Corp. is a major processed foods company located in
 China. The Company commenced operations of Shandong Lorain, its
 first operating subsidiary, in 1995, to manufacture chestnut
 products and over years, it expanded its product lines to include
 canned, frozen and bulk foods, and convenience foods sold to
 domestic and international customers. The Company now has four
 manufacturing facilities. In the highly fragmented processed foods
 industry, Lorain has gained competitive advantages through its
 proprietary brands and advanced technologies and currently sells
 over 192 products to19 provinces and administrative regions in China
 as well as to 42 foreign countries.
Company: American Tony Pharmaceuticals Inc
Ticker Symbol & Exchange: OTC BB/ATNY.OB
Investor Relations Contact: Leslie Wolf-Creutzfeldt
Investor Relations Contact
 Phone: 646-284-9472
Web: www.tmyy.com.cn
Date of Presentation: Nov 12 at 9:30am
Tongli Pharmaceutical (USA), Inc. develops, manufactures and markets
 pharmaceutical and health care products through its wholly-owned
 subsidiary, Harbin Tianmu Pharmaceutical Co., Ltd. ("Tianmu
 Pharmaceutical"). Tianmu Pharmaceutical was founded in 1999 in
 Harbin, hub of the Northern Pharmaceutical base of China. The
 company acquired the GMP certificate in 2003 and was listed on the
 OTC Bulletin Board on July 29, 2008. With a cohesive management team
 and committed staff, Tongli is providing the best quality
 pharmaceutical products at a very competitive price. The company is
 targeting the vast Chinese market with a vision of extending its
 footprint to East Asia and Russia.
Company: Anadis Limited
Ticker Symbol & Exchange: ASX: ANX
Investor Relations Contact: Dr. Oren Fuerst
Investor Relations Contact
 Phone: 646 259 3321
Web: www.anadis.com
Date of Presentation: 11/12/2008
Anadis is a biopharmaceutical company focused on antigen-primed,
 dairy-derived health products. Anadis' proprietary and low-cost
 antibody manufacturing technology enables it to rapidly develop
 polyclonal antibody and other protein-based oral therapies to a
 range of important infectious and immune- mediated diseases.
Large target markets with products reaching the markets in 2-3 years,
 all using the same platform.
-- Cancer therapy-related Mucositis (clinical trial in Israel
 started)
-- HIV/AIDS (major clinical trial in Australia just announced)
-- Diabetes (clinical trial to be initiated within a few months
 pending a transaction)
-- Influenza (clinical trial to begin during the year)
Commercial products : E.coliTravelers' Diarrhea and Rotavirus
 infection
Company: Argentex Mining Corporation
Ticker Symbol & Exchange: TSX-V:ATX;OTCBB:AGXM
Investor Relations Contact: Primoris Group Inc.
Investor Relations Contact
 Phone: 1-866-594-7687
Web: www.argentexmining.com
Date of Presentation: Tues. November 11, 2008, 11:10 a.m.
Argentex Mining Corporation is a junior mining exploration company
 with extensive holdings in Argentina's Patagonia region, including
 its flagship Pinguino property in Santa Cruz province. The company
 holds 100% mineral rights to this property, which has a unique
 commodity profile: gold, silver, lead, zinc and indium. Argentex's
 exploration team has taken Pinguino from the grassroots stage to a
 significant drill-tested deposit (30,000+ meters completed) in just
 a few years. Argentex also owns 100% mineral rights to more than 30
 properties with over 377,490 acres (152,766 hectares) of prospective
 land located in Argentina's Santa Cruz and Rio Negro provinces.
Company: Arrow Energy Limited
Ticker Symbol & Exchange: AOE.AX (ASX)
Investor Relations Contact: Graham Yerbury
Investor Relations Contact
 Phone: +61 7 31053466
Web: www.arrowenergy.com.au
Date of Presentation: Monday November 10, 2008
Arrow Energy is an ASX 100 listed Coal Bed Methane Company operating
 in Australia and South East Asia. Arrow's Australian tenements are
 estimated to have 70Tcf of gas in place. Arrow and it's joint
 venture partner Shell are moving towards developing the world's
 first CBM to LNG operation in the Gladstone port with initial plans
 for a 1.5mtpa plant in operation by 2012. Arrow has also integrated
 downstream into the production of electricity with access to 370MW
 of electricity offtake. Arrow is currently completing exploration
 and appraisal activity in India and Vietnam with business
 development opportunities in China and Indonesia.
Company: Asia Time Corporation
Ticker Symbol & Exchange: Amex: TYM
Investor Relations Contact: Brandi Floberg
Investor Relations Contact
 Phone: 310-277-4711
Web: www.asiatimecorp.com
Date of Presentation: November 10, 2008 at 10:20 a.m. ET
Asia Time is a Hong Kong distributor of timepiece movements. The
 Company currently distributes approximately 350 products, including
 both watch movements and complete watches, representing 30 vendors.
 These products are supplied to Asia Time's more than 300 customer
 manufacturers of globally branded watches. The Company's
 distribution centers and sales offices are located throughout Hong
 Kong and China.
Asia Time is well positioned to capitalize on growth opportunities in
 developed markets and especially in the under-penetrated market for
 watch movements and completed watches in China. The Company holds
 strong competitive advantages in quartz and mechanical movements,
 and it seeks to expand up the watch market value chain into low-cost
 China-based manufacturing of proprietary branded movements and
 complete watches.
Company: Aurora Oil & Gas Limited
Ticker Symbol & Exchange: "AUT" on ASX
Investor Relations Contact: Jon Stewart (Exec Chairman)
Investor Relations Contact [email protected], 61 89440
 Phone: 2626
Web: www.auroraoag.com.au
Date of Presentation: 11/10/2008
Aurora Oil & Gas Limited is an Australian quoted public company (ASX:
 AUT) focused in North America. Aurora participates in advanced
 exploration/development opportunities with large size potential.
Aurora's principal asset is its substantial landholdings in the
 recently discovered Sugarkane Field in South Texas. Sugarkane Field
 is a potential multi TCFe gas and condensate resource.
The Sugarkane Field was discovered in 2006 with an exploration well
 that intersected a unique over pressured, porous condensate rich
 Austin Chalk formation within the region. Several follow up wells
 have been successfully drilled and appraisal and development
 drilling of this field is under way.
Company: Ausam Energy Corporation
Ticker Symbol & Exchange: AZE.V, ASMEF.OB
Investor Relations Contact: Mark G. Avery
Investor Relations Contact
 Phone: 1.863.678.2200
Web: www.ausamenergy.com
Date of Presentation: 11/11/2008
Ausam is a public company engaged in oil and gas exploration and
 development. Ausam, through its U.S. subsidiary Noram Resources,
 Inc, has acquired a diverse portfolio of oil and gas leases and
 prospects in Texas, Louisiana, Mississippi, Alabama and Arkansas.
 Ausam's growth strategy includes the systematic development of its
 current holdings and selective corporate transactions. The Company
 trades under the symbol "AZE" on the TSX Venture Exchange and the
 symbol "ASMEF" on the OTC Bulletin Board
Company: Avanir Pharmaceuticals
Ticker Symbol & Exchange: AVNR / NASDAQ
Investor Relations Contact: Eric Benevich
Investor Relations Contact
 Phone: (949)389-6776
Web: www.avanir.com
Date of Presentation: November 11, 2008 at 4:55pm ET
AVANIR Pharmaceuticals is a biopharmaceutical company focused on
 developing novel treatments for central nervous system conditions.
 AVANIR's lead product candidate, Zenvia(TM), is in Phase III
 development for two indications; pseudobulbar affect (PBA) and
 diabetic peripheral neuropathic (DPN) pain. Zenvia is the subject of
 an approvable letter from the FDA for the PBA indication. The
 Company is now conducting a confirmatory Phase III study testing a
 lower dose formulation intended to improve safety and tolerability.
 Top line results are expected in Q3 of 2009. Please review AVANIR's
 SEC filings or www.avanir.com for further information regarding
 risks and uncertainties affecting the Company.
Company: Bio-Bridge Science, Inc.
Ticker Symbol & Exchange: BGES - OTCBB
Investor Relations Contact: Chris Young
Investor Relations Contact
 Phone: (630) 928-0869
Web: http://www.bio-bridge-science.com
Date of Presentation: 11/12/2008
Bio-Bridge Science is a biotechnology company engaged in the
 commercial development of vaccines and related products for the
 prevention and treatment of human diseases. The company is currently
 developing oral vaccines against HIV, HPV and colon cancer. In
 addition, the Company has a subsidiary that produces bovine serum
 and plans to form a joint venture to produce cell culture medium for
 vaccine production.
Company: BioDelivery Sciences International
Ticker Symbol & Exchange: BDSI (NASDAQ)
Investor Relations Contact: Bryan Armstrong
Investor Relations Contact
 Phone: 312-553-6707
Web: [email protected]
Date of Presentation: Mon. November 10, 2008 at 10:20 am
BioDelivery Sciences is a specialty pharmaceutical company leveraging
 its novel and proprietary patented drug delivery technologies to
 develop and commercialize, either on its own or in partnerships, new
 applications of proven therapeutics.
The development strategy focuses on the utilization of the FDA's
 505(b)(2) approval process to obtain timely and efficient approval
 of new formulations of previously approved therapeutics which
 incorporate the company's drug delivery technologies, BioErodible
 MucoAdhesive (BEMA) and Bioral.
BDSI is addressing important unmet market needs with a focus on
 formulations of pharmaceuticals aimed principally at treatment
 opportunities in areas such as pain and fungal infections. The
 company's lead product ONSOLIS (BEMA Fentanyl) is currently under
 review at FDA with an anticipated approval 1H 2009.
Company: BioSante Pharmaceuticals, Inc.
Ticker Symbol & Exchange: BPAX NASDAQ
Investor Relations Contact: Phillip Donenberg
Investor Relations Contact 847-478-0500 ext 100
 Phone:
Web: www.biosantepharma.com
Date of Presentation: 11/12/2008
BioSante is a specialty pharmaceutical company focused on developing
 products for female sexual health, menopause, contraception and male
 hypogonadism. BioSante's lead products include LibiGel(R)
 (transdermal testosterone gel) in Phase III clinical development by
 BioSante under a U.S. Food and Drug Administration (FDA) SPA
 (Special Protocol Assessment) for the treatment of female sexual
 dysfunction (FSD), and Elestrin(TM) (estradiol gel) developed
 through FDA approval by BioSante, indicated for the treatment of
 moderate-to-severe vasomotor symptoms associated with menopause,
 currently marketed in the U.S. Also in development are Bio-T-
 Gel(TM), a testosterone gel for male hypogonadism, and an oral
 contraceptive in Phase II clinical development using BioSante
 patented technology.
Company: Boots & Coots
Ticker Symbol & Exchange: NYSE Alternext: WEL
Investor Relations Contact: Jennifer Tweeton
Investor Relations Contact
 Phone: 281-931-8884
Web: www.boots-coots.com
Date of Presentation: November 11, 10:45 am Eastern
Boots & Coots provides a suite of integrated pressure control
 services to oil and gas exploration companies around the world. Our
 services are designed to enhance production and reduce the number
 and severity of critical well events such as well fires, blowouts or
 other losses of control at the well. Our Well Intervention segment
 includes services performed by hydraulic workover and snubbing units
 and the rental of pressure control tools. This segment also includes
 prevention and risk management services offered through our
 Safeguard and risk mitigation programs. Our Response segment
 consists of personnel, equipment and services provided during a
 critical well event.
Company: BPZ Energy
Ticker Symbol & Exchange: NYSE Alternext:BPZ
Investor Relations Contact: Greg Smith
Investor Relations Contact
 Phone: 281 752 1240
Web: www.bpzenergy.com
Date of Presentation: 11/10/2008
Houston based BPZ Energy is an oil and gas exploration and production
 company which has exclusive license contracts for oil and gas
 exploration and production covering approximately 2.4 million acres
 in four properties in northwest Peru. It also owns a minority
 working interest in a producing property in southwest Ecuador. The
 Company is currently executing the development of the Corvina oil
 discovery, the redevelopment of the Albacora oil field, and the
 exploration of Block XIX, in parallel with the execution of an
 integrated gas-to-power strategy, which includes generation and sale
 of electric power in Peru and the development of a regional gas
 marketing strategy. The Company's website at www.bpzenergy.com
 provides additional information about the Company's plans, including
 photographs and other information with respect to its operat
Company: Bradmer Pharmaceuticals Inc.
Ticker Symbol & Exchange: BMR (TSX)
Investor Relations Contact: Ross Marshall, Equicom Group
Investor Relations Contact 416-815-0700 x238
 Phone:
Web: http://www.bradmerpharma.com
Date of Presentation: 11/12/08, 10:45 a.m.
Bradmer Pharmaceuticals is a biopharmaceutical company established in
 2006 to advance a promising new drug for glioblastoma multiforme
 patients into a pivotal Phase III trial. Neuradiab(TM) (formerly
 referred to as "I-131 mu81C6" in scientific literature) is a
 radiolabeled monoclonal antibody that has been delivered to more
 than 200 patients in its significant Phase I and II clinical history
 at Duke University. It has been designed to deliver a precise
 localized radiation boost dose specifically to post-surgical
 residual cancer cells via single injection. Our multi-center
 randomized trial for patients with newly-diagnosed GBM is underway
 at leading brain tumor treatment centers across the US. This Phase
 III trial will investigate Neuradiab as an adjuvant therapy to
 surgery, external beam radiation and temozolomide.
Company: Bravo Venture Group Inc.
Ticker Symbol & Exchange: BVG-TSX.Venture
Investor Relations Contact: Jay Oness
Investor Relations Contact
 Phone: 1-888-456-1112/604-641-2771
Web: www.bravoventuregroup.com
Date of Presentation: Tuesday, November 11th at 2:25pm
The company is active in NW British Columbia, Alaska and Nevada. The
 VMS/Epithermal gold/silver Homestake Ridge project in BC is
 advancing with excellent drill results and an NI43-101 compliant
 technical report (being updated) which reported an inferred resource
 of +900,000 oz/Au. Recent certified assays from the now completed
 8,400 metre drill program returned BONANZA grade intercepts;73metres
 averaging 21g/t gold with an intercept of 7.65metres averaging
 181.58 g/t gold, as well, another intercept recorded 22.29metres of
 513.7 g/t silver including a 2.71metre bonanza grade averaging 2,502
 g/t silver.
Other project include the VMS Woewodski Island project in Alaska and
 13 projects in Nevada.
Company: CanAlaska Uranium Ltd
Ticker Symbol & Exchange: TSX.V: CVV
Investor Relations Contact: Emil Fung, V.P. Corp. Dev.
Investor Relations Contact
 Phone: 604 688 3211
Web: www.canalaska.com
Date of Presentation: Tuesday, November 11th 2008 @ 14:00
CANALASKA URANIUM LTD. (CVV -- TSX.V) is undertaking uranium
 exploration in nineteen 100%-owned and two optioned uranium projects
 in Canada's Athabasca Basin, supplier of 30% of the world's uranium
 and home to the planet's richest uranium mines. Since September
 2004, the Company has aggressively acquired one of the largest land
 positions in the region, comprising over 2,500,000 acres (10,117 sq.
 km or 3,906 sq. miles). To-date, CanAlaska has expended over Cdn$45
 million and has delineated multiple uranium targets. The company is
 financially-supported by numerous strategic partners, including,
 Mitsubishi Development Pty, a subsidiary of Japanese conglomerate
 Mitsubishi Corporation, and a consortium of leading Korean energy
 companies comprising Hanwha Corp., KEPCO, KORES and SK Energy.
Company: Candax Energy Inc.
Ticker Symbol & Exchange: CAX: TSX
Investor Relations Contact: Lindsay Carpenter
Investor Relations Contact [email protected], 416-868-1079 ext.
 Phone: 239
Web: www.candax.com
Date of Presentation: 11/11/2008
Candax Energy Inc. is a Canadian based oil and natural gas company
 engaged in the exploration, acquisition, development and production
 of crude oil and natural gas, with emphasis on Africa and the Middle
 East. Candax has three producing fields in Tunisia: offshore at El
 Bibane, and onshore at Ezzaouia and Robbana and significant upside
 potential through its Deep Triassic play, its onshore Chaal gas
 discovery and its promising early exploration work in Madagascar.
 Candax's net production for Q3 is expected to average 1,600 boepd
 (1,200 bopd and 2 MMcf/d) and production for Q4 is forecast at 2,800
 boepd (2,000 bopd and 4.7 MMcf/d).
Company: CAS Medical Systems, Inc.
Ticker Symbol & Exchange: CASM
Investor Relations Contact: Susan Carron
Investor Relations Contact
 Phone: 203-488-6056
Web: www.casmed.com
Date of Presentation: 11/12/2008
CASMED is a leading developer and manufacturer of medical devices for
 non-invasive patient monitoring. The Company's FORE-SIGHT Absolute
 Cerebral Oximeter is the only cerebral oximeter available with FDA
 clearance for non-invasive, continuous measurement of absolute
 cerebral tissue oxygen saturation for neonates, infants, children
 and adults. This information helps avert brain damage or death
 during surgery and in critical care situations by allowing
 clinicians to identify patients with dangerously low levels of
 cerebral oxygen and intervene to reverse the condition.
The Company's product lines also include bedside patient vital signs
 monitors, proprietary non-invasive blood pressure measurement
 technology, blood pressure cuffs and products for neonatal intensive
 care.
Company: Cavico Corp.
Ticker Symbol & Exchange: OTCBB: CVIC
Investor Relations Contact: Roger Ellis
Investor Relations Contact Tel: 310-477-9800 Ext 106
 Phone:
Web: www.cavicocorp.com
Date of Presentation: 11/11/2008
Cavico Corp. is a major infrastructure contractor with over 3,000
 employees, including 700 engineers. Headquartered in Hanoi, Vietnam,
 Cavico operates nationwide in Vietnam with an expanding global
 presence through direct and indirect subsidiaries. Cavico is the
 only firm using the latest Tunnel Boring Machine (TBM) Technology in
 Vietnam. As an essential participant in the development of Vietnam's
 infrastrcuture to support Asia's second highest growth rate, Cavico
 has a focus on large construction projects for hydropower
 facilities, dams, bridges, tunnels, roads, and mines. Cavico also
 participates in ownership investments related to its core competency
 in energy, mining, cement plants, and urban development companies.
Company: Celsion Corporation
Ticker Symbol & Exchange: NASDAQ: CLSN
Investor Relations Contact: Geoffrey Grande, CFA
Investor Relations Contact
 Phone: 617-747-1721
Web: http://www.celsion.com/
Date of Presentation: Nov. 11th, from 4:30 to 4:55 PM
Celsion Corporation is an oncology drug development company focused
 on addressing cancers of high unmet medical needs. The proprietary
 drug platform - heat activated liposomal technology - effectively
 targets high concentrations of chemotherapeutics to organs of
 interest. The lead drug candidate - ThermoDox - is currently in
 global Phase III trials for liver cancer in 7 countries. Additional
 drug candidates - liposomal docetaxel and liposomal carboplatin -
 are currently in preclinical development. Celsion has research,
 license or commercialization agreements with leading institutions
 such as the NIH-NCI, Philips, Duke, University of Hong Kong,
 Cleveland Clinic, North Shore-LIJ, and 40 other leading medical
 institutions worldwide.
Company: China Armco Metals, Inc.
Ticker Symbol & Exchange: OTC BB: CNAM
Investor Relations Contact: HC International, Inc.
Investor Relations Contact Alan Sheinwald, 914-669-5340
 Phone:
Web: www.armcometal.com
Date of Presentation: 11/10/2008
China Armco Metals, Inc. imports, sells, distributes metal ores and
 non-ferrous metals throughout the PRC. Armco is also ennted into the
 metal recycling business. The Company's product lines include
 ferrous and non-ferrious ore such as iron ore, chrome ore, nickel
 ore, copper ore, magnese ore and steel billet. Raw materials are
 supplied from global suppliers in India, Hong Kong, Nigeria, Brazil,
 Turkey, the Philippines and Libya. Beginning in the second quarter
 2009, Armco expects to begin operations in its steel recycling and
 scrap metal supply. The recycling facility is expected to be capable
 of recycling one million metric tons of scrap metal per year which
 will position the Company as one of the top 10 recyclers of scrap
 metal in China.
Company: China Direct, Inc.
Ticker Symbol & Exchange: NASDAQ: CDS
Investor Relations Contact: Lillian Wong
Investor Relations Contact 954.363.7333 ext. 317
 Phone:
Web: www.ChinaDirectInc.com
Date of Presentation: 11/10/2008
China Direct is a diversified management and advisory services
 organization which owns and consults business entities operating in
 the People's Republic of China. We operate two divisions: Management
 Services and Advisory Services. Our Management Services division
 acquires controlling interests of Chinese business entities. Our
 Advisory Services division provides consulting services to both
 Chinese entities seeking access to the U.S. capital markets and
 North American entities seeking business opportunities in the PRC.
 As a direct link to China, China Direct serves as a vehicle allowing
 investors to participate directly in the rapid growth of the Chinese
 economy. For more information, please visit www.ChinaDirectInc.com.
Company: China Green Agriculture Inc.
Ticker Symbol & Exchange: CGAG.OB
Investor Relations Contact: Ying Yang
Investor Relations Contact
 Phone: 626-623-2575
Web: www.cgagri.com
Date of Presentation: 11/12/2008
China Green Agriculture, through its wholly-owned subsidiary Shaanxi
 TechTeam Jinong Humic Acid Product Co., Ltd, develops, manufactures
 and distributes humic acid-based liquid compound fertilizers in 27
 provinces throughout China. The Company offers over 100 different
 varieties of fertilizers targeted to unique climate and soil
 specifications. China Green Agriculture's headquarters, based in
 Shaanxi Province, include extensive R&D facilities and cutting edge
 automated production lines. With one of the most recognizable brand
 names in Chinese green fertilizers today, the Company is one of the
 few fertilizer manufacturers in China that operates on a national
 scale.
Company: China Marine Food Group, Ltd.
Ticker Symbol & Exchange: OTC BB: CMFO
Investor Relations Contact: HC International, Inc.
Investor Relations Contact John Mattio, 914-669-5340
 Phone:
Web: www.china-marine.cn
Date of Presentation: 11/10/2008
Founded in 1994, China Marine Food Group, Ltd. processes and
 distributes processed seafood snack-type products, fresh and frozen
 marine catch to five provinces in the PRC and select international
 markets. Since inception, China Marine has grown steadily, received
 "The Famous Brand" and "Green Food" awards, and positioned its
 "Mingxiang"brand as a category leader in 1,300 retail sales points
 in the PRC. The Company is committed to the highest standard of
 quality control and is strategically located in Fujian Province, one
 of the largest coastal provinces in the PRC and a vital navigation
 hub bewteen the East China Sea and the South China Sea. For the
 first six months ended June 30, 2008, revenue and net income
 increased 35.9% and 39.2% to $23.8 million and $6.0 million
 respectively.
Company: China North East Petroleum Holdings
 Ltd.
Ticker Symbol & Exchange: CNEH OTCBB
Investor Relations Contact: Chao Jiang
Investor Relations Contact
 Phone: 212-307-3568
Web: www.cnepetroleum.com
Date of Presentation: 11/12/2008
China North East Petroleum Holdings Limited (OTCBB: CNEH), through
 its subsidiaries, engages in the extraction and production of crude
 oil in Northern China. The company was founded in 2002 and is based
 in Harbin China and New York. The company owns 20 years leasing
 rights in Jilin Qian'an Oil Field, an oil field located
 approximately 9 kilometers southwest of Qian'an city Jilin Province
 China with a total exploration area of approximately 11,663 acres.
 The Company has a guaranteed arrangement with the Jilin Refinery of
 PetroChina to sell its produced crude oil for use in the China
 marketplace. China North East Petroleum currently has about 312
 employees and 214 wells within four oilfields in Northern China and
 has plans for additional well drilling projects.
Company: China Wind Systems, Inc.
Ticker Symbol & Exchange: CWSI.OB
Investor Relations Contact: Crocker Coulson
Investor Relations Contact
 Phone: (646) 213-1915
Date of Presentation: 4:05 p.m. 11th November 2008
China Wind Systems, Inc. supplies forged rolled rings to the wind
 power and other industries and industrial equipment to the textile
 and energy industries in China. With its newly finished state-of-
 the-art production facility, the Company is expected soon to
 significantly increase its shipment of high- precision rolled rings
 and other essential components primarily to the wind power and other
 industries.
Company: China Yingxia International, Inc.
Ticker Symbol & Exchange: CYXI.OB
Investor Relations Contact: CCG Investor Relations
Investor Relations Contact Crocker Coulson, 646-213-1915
 Phone:
Web: www.chinayingxia.com
Date of Presentation: November 12th at 10:45 am
China Yingxia International, Inc. is primarily engaged in the
 development, production and sales of health food products in China.
 The Company sells over 235 stock keeping units (SKUs) in five
 product categories including soybean-based food and drinks, Longgu
 golden millet enriched products, raw cacti, cactus-based herbal
 supplements, personal care products, Nestle products and organic
 rice products. Yingxia was founded in 1998 and is headquartered in
 Harbin, Heilongjiang province, People's Republic of China.
Company: ChinaCast Education Corporation
Ticker Symbol & Exchange: CAST - NASDAQ
Investor Relations Contact: Michael Santos
Investor Relations Contact
 Phone: 202-361-3403
Web: www.chinacasteducation.com
Date of Presentation: Nov. 10, 2008
ChinaCast Educations Corporation is a leading for-profit, post-
 secondary education and e-learning services provider in China. We
 provide fully accredited four year degree and two year diploma post-
 secondary education programs through our university in Chongqing,
 the Foreign Trade and Business College (FTBC) of Chongqing Normal
 University. We provide our e-learning services to post-secondary
 institutions, K-12 schools, government agencies and corporations via
 our nationwide satellite broadband network. These services include
 interactive distance learning applications, multimedia education
 content delivery, English language training and vocational training
 courses.
Company: Cipher Pharmaceuticals Inc.
Ticker Symbol & Exchange: DND: TSX
Investor Relations Contact: Craig Armitage
Investor Relations Contact (416) 815-0700 x278
 Phone:
Web: www.cipherpharma.com
Date of Presentation: 11/12/2008
Cipher Pharmaceuticals is an emerging specialty pharmaceutical
 company with a late-stage product portfolio. The Company is focused
 on commercializing novel formulations of successful, currently
 marketed molecules using advanced drug delivery technologies.
Cipher's lead compound, CIP-FENOFIBRATE, received final approval from
 the U.S. Food and Drug Administration and Health Canada in the first
 quarter of 2006. The product is being marketed in the United States
 by Kowa Pharmaceuticals America (formerly ProEthic Pharmaceuticals)
 under the label Lipofen(R). In addition, Cipher is developing novel
 formulations of the pain reliever tramadol and the acne treatment
 isotretinoin.
Company: Clinuvel Pharmaceuticals Limited
Ticker Symbol & Exchange: ASX: CUV, ADR: CLVLY
Investor Relations Contact: Colin Mackie
Investor Relations Contact
 Phone: 61 3 9660 4900
Web: www.clinuvel.com
Date of Presentation: November 12, 2008 - 3:15PM Louis Rm
Clinuvel Pharmaceuticals Limited (Clinuvel) is an Australian
 biopharmaceutical company developing a first-in-class
 photoprotective drug afamelanotide* (CUV1647) for use in a range of
 UV and light related skin disorders.
Afamelanotide provides skin protection against UV radiation (UVR) as
 it stimulates the body's natural ability to produce eumelanin, the
 dark pigment of the skin which is known to have photoprotective
 properties.
Clinuvel has identified five indications and has two Phase III trials
 underway, aswell as three Phase II trials. Clinuvel aims to have
 afamelanotide in the market by 2010.
Company: Comanche Clean Energy Corp.
Ticker Symbol & Exchange: OTCBB:CGYYF
Investor Relations Contact: Todd M. Pitcher
Investor Relations Contact
 Phone: 760-798-4938
Web: www.comanchecleanenergy.com
Date of Presentation: November 10 at 10:20AM
Comanche Clean Energy is a Brazil-based producer of ethanol and
 biodiesel from multiple feed-stocks in its own facilities and grows
 the majority of the sugar-cane feedstock that it requires for
 producing ethanol, creating a vertically integrated model. The
 company's customers for ethanol are fuel distributors and trading
 companies and its current biodiesel sales are to Petrobras, the
 Brazilian oil company. Comanche owns and operates two ethanol
 facilities and one biodiesel facility in Brazil. Through the six
 months ended, June 30, 2008, revenues were $22.1 million, up from
 $1.1 million reported for the same period last year.
Company: CombinatoRx, Incorporated
Ticker Symbol & Exchange: CRXX
Investor Relations Contact: Gina Nugent
Investor Relations Contact
 Phone: 617-301-7099
Web: www.combinatorx.com
Date of Presentation: Nov. 10, 2008
CombinatoRx, Incorporated (CRXX) is pioneering the new field of
 synergistic combination pharmaceuticals and has a broad product
 portfolio in phase 2 clinical development. Going beyond traditional
 combinations, CombinatoRx creates product candidates with novel
 mechanisms of action striking at the biological complexities of
 human disease. The lead programs in the CombinatoRx portfolio are
 advancing into later stage clinical trials based on the strength of
 multiple positive phase 2a results. This portfolio is internally
 generated from the CombinatoRx proprietary drug discovery technology
 which provides a renewable and previously untapped source of novel
 drug candidates. The Company was founded in 2000 and is located in
 Cambridge, Massachusetts.
Company: Cougar Biotechnology, Inc.
Ticker Symbol & Exchange: NASDAQ: CGRB
Investor Relations Contact: Mariann Ohanesian
Investor Relations Contact
 Phone: 310-943-8040
Web: www.cougarbiotechnology.com
Date of Presentation: 11/12/2008
Cougar Biotechnology is a development stage biopharmaceutical company
 based in Los Angeles, California that in-licenses novel therapeutics
 and develops such therapeutics for the treatment of cancer. Our
 strategy is to license technologies that have previously been tested
 in clinical trials, enabling us to obtain an initial indication of
 the drug's safety and biological activity in humans before
 committing capital to the drug's development.
Cougar's oncology portfolio includes CB7630, a targeted inhibitor of
 the 17alpha-hydroxylase/c17,20 lyase enzyme, which is currently
 being tested in a Phase III clinical trial in prostate cancer;
 CB3304, an inhibitor of microtubule dynamics, which is currently in
 a Phase I trial in multiple myeloma; and CB1089, an analog of
 vitamin D, which has been clinically tested in a number of solid
 tumor types.
Company: CPEX Pharmaceuticals, Inc.
Ticker Symbol & Exchange: NASDAQ : CPEX
Investor Relations Contact: Laura Okpala
Investor Relations Contact 617-583-1306, [email protected]
 Phone:
Web: www.cpexpharm.com
Date of Presentation: Tuesday November 11, 2008 2:30PM
CPEX Pharmaceuticals, Inc. is an emerging specialty pharmaceutical
 company primarily focused on the development of Nasulin(TM), an
 intranasal insulin drug, currently in Phase II trials for diabetes.
 CPEX has a proprietary drug delivery platform technology, CPE-
 215(R), which allows it to expand its internal pipeline of products
 beyond Nasulin and generate revenue from partnering. CPEX has
 licensed applications of CPE-215 to Auxilium Pharmaceuticals, which
 launched Testim(R) in 2003. CPEX received royalties of $11.1 million
 in 2007 from sales of Testim. In addition, CPEX has a partnership
 with Serenity Pharmaceuticals for the development of a urology
 product incorporating its CPE-215 platform technology.
Company: Crosshair Exploration & Mining Corp
Ticker Symbol & Exchange: CXZ:AMEX, CXX:TSX
Investor Relations Contact: Jennifer Richards
Investor Relations Contact 604-681-8030 x.229
 Phone:
Web: www.crosshairexploration.com
Date of Presentation: 11/12/2008 12:25
Crosshair is a leading junior exploration company focused on
 exploring and developing uranium in the Central Mineral Belt of
 Labrador, which is fast emerging as the next big uranium district in
 Canada.
Crosshair is demonstrating the multi-deposit potential of the project
 by successfully developing and drilling several new uranium targets
 and currently controls four existing NI 43-101 compliant resources.
Crosshair's gold and Volcanic Hosted Massive Sulphide projects in
 Newfoundland, are slated for a dividend spin-out to shareholders.
 Crosshair currently trades on the Toronto Stock Exchange (CXX:TSX)
 and the American Stock Exchange (CXZ:AMEX).
Company: Cue Energy Resources Limited
Ticker Symbol & Exchange: ASX : CUE
Investor Relations Contact: Pauline Moffatt
Investor Relations Contact
 Phone: 61 3 9670 8668
Web: www.cuenrg.com.au
Date of Presentation: 11/11/2008
Cue is a small Australian independent, SE Asia and Australasian
 focussed, oil and gas exploration and production company. Cue has
 current oil production in Papua New Guinea and Indonesia with
 additional oil production beginning in New Zealand in late 2008. Gas
 production is expected to begin in Indonesia in 2009 and 2010.
 Appraisal drilling on other gas and oil discoveries is expected in
 2009.
Cue also holds a balanced portfolio of exploration areas in
 Australia, Papua New Guinea, New Zealand and Indonesia in which
 there are ongoing seismic and exploration drilling programs, and has
 interests in approximately 280 net BCF of contingent gas resources
 in Australia and Papua New Guinea.
Company: Cyclacel Pharmaceuticals, Inc.
Ticker Symbol & Exchange: CYCC - NASDAQ
Investor Relations Contact: Corey Sohmer
Investor Relations Contact
 Phone: 908-517-7330
Web: www.cyclacel.com
Date of Presentation: 11/12/2008
Cyclacel is a biopharmaceutical business dedicated to discovery,
 development and commercialization of novel, targeted drugs to treat
 cancer and other serious disorders. Three orally-available drugs are
 in clinical development: sapacitabine, in randomized Phase 2 studies
 for the treatment of elderly acute myeloid leukemia, myelodysplastic
 syndromes and cutaneous T-cell lymphoma; seliciclib, in randomized
 Phase 2 studies for the treatment of non-small cell lung and
 nasopharyngeal cancers; and CYC116, in Phase 1 for solid tumors.
 Cyclacel's ALIGN subsidiary sells three products in the US treating
 the effects of radiation or chemotherapy in cancer patients:
 Xclair(R) Cream, Numoisyn(TM) Liquid and Lozenges.
Company: Cytomedix
Ticker Symbol & Exchange: AMEX:GTF
Investor Relations Contact: Enrique Briz
Investor Relations Contact
 Phone: 212/888-4848
Web: http://www.cytomedix.com
Date of Presentation: Wednesday, Nov. 12, 2008 (2:25 pm)
Cytomedix is a biotechnology company that develops, sells, and
 licenses regenerative biological therapies, including the
 AutoloGel(TM) System, a device for the production of platelet rich
 plasma ("PRP") gel derived from the patient's own blood. The
 AutoloGel(TM) System is cleared by the Food and Drug Administration
 ("FDA") for use on a variety of exuding wounds. The Company is
 currently pursuing a multi-faceted strategy to penetrate the chronic
 wound market with its AutoloGel(TM) System. The Company is also
 moving forward with the development of other product candidates in
 its pipeline. Most notably is its CT-112 product, an anti-
 inflammatory peptide, that has shown promise in pre-clinical
 testing, and for which the Company is currently preparing an
 Investigational New Drug (IND) application for the FDA.
Company: Deer Consumer Products, Inc.
Ticker Symbol & Exchange: DCPI (OTC BB)
Investor Relations Contact: Ms. Yong MeiWang
Investor Relations Contact
 Phone: 86 755-86028285
Web: www.deerinc.com
Date of Presentation: 11/10/2008 14:25
Deer Consumer Products, Inc. is a US public company headquartered in
 China. Supported by more than 75 patents, Deer is a market leader in
 the design, manufacture and sale of home and kitchen electronics
 targeting the vast Chinese domestic consumer markets as well as
 customers in more than 40 countries worldwide. Deer's product lines
 include blenders, juicers, pressure cookers and other home
 electronics designed to improve home lifestyles in today's fast
 paced society. With more than 100 global and domestic clients
 including Black & Decker, Disney, Toastmaster, Home Depot and Wal-
 Mart, Deer has enjoyed rapid sales and earnings growth.
Company: Delcath Systems, Inc.
Ticker Symbol & Exchange: DCTH NASDAQ
Investor Relations Contact: Strategic Growth International
Investor Relations Contact Richard Cooper, 212.838.1444
 Phone:
Web: www.delcath.com
Date of Presentation: 11/11/2008
Delcath Systems, Inc. is a medical technology company specializing in
 cancer treatment. The Company is testing a proprietary, patented
 drug delivery system for the treatment of liver cancers. Delcath's
 novel drug delivery platform is testing the delivery of ultra-high
 doses of anti-cancer drugs to the liver while preventing these high
 doses of drug from entering the patient's bloodstream. The Company
 is currently enrolling patients in Phase III and Phase II clinical
 studies for the treatment of liver cancers using high doses of
 melphalan. The Company's intellectual property portfolio consists of
 twenty-eight patents worldwide, including the U.S., Europe, Asia and
 Canada.
Company: Derma Sciences Inc
Ticker Symbol & Exchange: DSCI OTCBB
Investor Relations Contact: Rudy Barrio @ Allen&Caron Inc
Investor Relations Contact
 Phone: 212 691 8087
Web: www.dermasciences.com
Date of Presentation: Wednesday, November 12, 2008 @ 2:00
Derma Sciences is a global manufacturer and marketer of advanced
 wound-care products. Its key product, MEDIHONEY, is sold throughout
 the world. The product has been shown to be effective in a variety
 of wounds and burns, and was recently the focus of a large-scale
 randomized controlled trial on leg ulcers. Derma has two products in
 development: the BIOGUARD(TM) line of barrier gauze dressings, and
 DSC127, the company's novel angiotensin analog for accelerated wound
 healing and scar reduction. The barrier technology was licensed from
 Quick-Med in Q1 of 2007 and is pending its initial FDA marketing
 clearance. DSC127 was licensed from The University of Southern
 California in Q4 of 2007 and is entering into a Phase II study, with
 anticipated initial patient enrollment to begin in 2008.
Company: DOR BioPharma, Inc.
Ticker Symbol & Exchange: DORB: OTCBB
Investor Relations Contact: Evan Myrianthopoulos
Investor Relations Contact
 Phone: 609-538-8200
Web: www.dorbiopharma.com
Date of Presentation: 11/10/2008
DOR BioPharma is a late-stage biopharmaceutical company developing
 products to treat life-threatening side effects of cancer treatments
 and serious gastrointestinal diseases, and vaccines for certain
 bioterrorism agents. DOR's lead product, orBec(R) (oral
 beclomethasone dipropionate or BDP), is a potent, locally acting
 corticosteroid being developed for the treatment of gastrointestinal
 Graft-versus-Host disease (GI GVHD), a common and potentially life-
 threatening complication of bone marrow transplantation. DOR
 anticipates market potential for orBec(R) for the treatment of GI
 GVHD to be approximately 60% of the more than 10,000 allogeneic
 hematopoietic cell transplantations that occur each year in the US,
 with similar numbers in Europe.
Company: ECU Silver Mining Inc.
Ticker Symbol & Exchange: TSX: ECU
Investor Relations Contact: Christopher Haldane
Investor Relations Contact 416.868.1079 ex.237
 Phone:
Web: www.ecu.ca
Date of Presentation: 11/10/2008
ECU Silver Mining Inc. is focused on the exploration, development and
 mining of gold, silver and base metals at its Velardena District
 Properties in Durango, Mexico. The district is well known for its
 mining history and ECU holds three properties that include five
 historical mines. ECU has measured and indicated resources of 38
 million ounces and inferred resources of 179 million ounces of
 silver equivalent. ECU's goal is to establish a significant
 polymetallic mineral resource in the heart of Mexico's mining
 district. Our mission is to become a pre-eminent silver and gold
 producer through the development of existing, and additional
 potential resources at Velardena.
Company: eFuture Information Technology
Ticker Symbol & Exchange: Nasdaq:EFUT
Investor Relations Contact: Troe Wen
Investor Relations Contact
 Phone: 86 1051650988
Web: www.e-future.com.cn
Date of Presentation: 11/11/2008
eFuture Information Technology Inc. (NASDAQ: EFUT) is a leading
 provider of front-end supply chain management software and services
 in China. eFuture provides integrated software and services to
 manufacturers, distributors, wholesalers, logistics companies and
 retailers in China's front-end supply chain market, especially in
 the retail and FMCG industries. eFuture serves over 1,000 clients,
 including 15 Fortune 500 companies, over 900 retailers and over 200
 distributors in China. eFuture is one of IBM's premier business
 partners in Asia Pacific and also partners with Oracle, Microsoft,
 JDA, Motorola and Samsung Network China. eFuture has over 600
 employees and 20 branch offices across China.
Company: Enable Holdings, Inc
Ticker Symbol & Exchange: ENAB
Investor Relations Contact: Ryan Calverley
Investor Relations Contact 773.272.4414,
 Phone: [email protected]
Web: www.EnableHoldings.com
Date of Presentation: 11/10/2008
Enable Holdings Inc., is the world's leading excess inventory
 solutions company that links brand name sellers with customers
 around the globe. Enable Holdings, Inc. does this through its unique
 multi-channel asset-recovery solution that includes online auction
 platform solution uBid.com, fixed-price commerce solution
 RedTag.com, offline excess inventory solution RedTag Live!,
 business-to-business solution Dibu Trading Company, and private
 auction software solution Commerce Innovations. Brand name sellers
 are able to reduce distressed and excess inventories more
 efficiently and profitably than ever before, and achieve greater
 yield, while providing shoppers a connection to the world's most
 trusted brands at a value.
Company: Endocyte, Inc.
Investor Relations Contact: Vickey Buskirk
Investor Relations Contact
 Phone: 765-463-7175
Web: www.endocyte.com
Date of Presentation: 11/10/2008
Great progress has been made in the development of new drugs to treat
 cancer and other serious illness. However, these therapies are often
 administered at suboptimal doses because of their side effects on
 healthy tissues. The value of these therapies is further diminished
 because of the inability to predict if a patient will respond to a
 particular therapy. Endocyte is addressing both of these issues
 using a new "drug guidance" technology that is designed to deliver
 drugs directly to diseased cells. This guidance system is composed
 of a targeting ligand that attaches to a drug and then binds to
 receptors over-expressed on the membranes of diseased cells.
Company: Energy Fuels, Inc.
Ticker Symbol & Exchange: TSX: EFR
Investor Relations Contact: Gary Steele
Investor Relations Contact
 Phone: 303-974-2147
Web: www.energyfuels.com
Date of Presentation: 11/11/2008
Energy Fuels is pursuing a mission to build a fully integrated
 uranium and vanadium production company through exploration,
 development, mining, milling & sales. The Company is a conventional,
 underground miner, utilizing low risk techniques of drilling, split
 shooting, and diesel haulage of waste and ore to the surface.
 Current technology is applied wherever it will increase
 productivity, lower cost, and improve grade control. Primary
 activities include:
-- Developer and miner of southwest US U3O8 and V2O5 properties
-- Prudent property acquisition to maintain full pipeline for
 production
-- Property interests include six formerly producing U mines
-- Aggressively refurbishing two of those mines to return them to
 production
-- Licensing the 1000 tpd Pinon Ridge U/V mill, the first US mill for
 processing U to be built in 25 years
Company: Epic Energy Resources
Ticker Symbol & Exchange: EPCC - OTC BB
Investor Relations Contact: Lisa Elliott
Investor Relations Contact 713- 529-6600, [email protected]
 Phone:
Web: www.1epic.com
Date of Presentation: 11/11/2008
EPiC Energy Resources is a Houston based integrated energy services
 company. EPiC provides consulting, engineering, construction
 management, operations, maintenance, specialized training and data
 management services focused primarily on the upstream and midstream
 energy infrastructure. Services are provided through Pearl, a
 diversified engineering and energy services company; Carnrite, a
 management consulting company focused on providing strategic and
 operational consulting services to the broad energy industry; and
 EIS, a global training and data management services company. Epic's
 Pearl operations oversee projects primarily in the Rockies and has
 ongoing projects in the Middle East. Unconventional gas exploration
 and oil discoveries in the Rocky Mountains and other markets in the
 U.S. has driven strong demand for its services.
Company: Evolution Petroleum
Ticker Symbol & Exchange: EPM - AMEX
Investor Relations Contact: Lisa Elliott
Investor Relations Contact 713-529-6600, [email protected]
 Phone:
Web: evolutionpetroleum.com
Date of Presentation: 11/11/2008
Evolution Petroleum Corporation acquires known, onshore oil and gas
 resources and applies conventional and specialized technology to
 accelerate production and develop incremental reserves and value.
 With no debt and a strong balance sheet, the Company is well
 positioned to carry out its initiatives.
Principal assets include 4 MMBOE of proved and 3.1 MMBOE of probable
 reserves in the Giddings Field of central Texas, more than 13 MMBO
 of probable reserves associated with the 13,636 acre Delhi Field
 Holt Bryant Unit currently being redeveloped with CO2-EOR technology
 in northeast Louisiana, and leases covering approximately 18,000 net
 acres in two Woodford gas shale projects in Oklahoma. The Company is
 also actively engaged in developing new projects within its
 initiatives.
Company: First Majestic Silver Corp.
Ticker Symbol & Exchange: TSX. - FR
Investor Relations Contact: Dan McIntyre/Jill Arias
Investor Relations Contact
 Phone: 6046883033
Web: www.firstmajestic.com
Date of Presentation: Monday, November 10th. 2:50pm
First Majestic Silver Corp. is a pure silver producing mining company
 focused in Mexico. The Company strives for continued growth with a
 proven aggressive growth strategy based on the development of its
 existing assets and acquisition of advance staged silver projects
 that meet its growth profile.
This past year the Company focused on an extensive mine development
 campaign at each of its three operating silver mines in Mexico; the
 La Parrilla, the La Encantada, and the San Martin Silver Mines.
 Approximately, 90% of the Company's overall revenue is from the sale
 of silver. For the year ending 2007, First Majestic's produced 3.6
 million ounces compared to 1.6 million in 2006. In addition, at the
 year ended 2007, 164 million ounces of NI 43-101 compliant silver
 equivalent resources had been defined, compared to approximately 70
 million
Company: Fronteer Development Group
Ticker Symbol & Exchange: TSX/AMEX: FRG
Investor Relations Contact: Richard Moritz
Investor Relations Contact 1.877.632.4677 (TF/North America)
 Phone:
Web: www.fronteergroup.com
Date of Presentation: Monday, Nov. 10, 2008, 3:15 p.m.
Fronteer's vision is to become a multibillion-dollar, gold-growth
 company advancing a pipeline of projects from exploration through to
 production. Fronteer has an interest in several major gold projects
 in Nevada and Turkey. The company's Nevada projects include
 Northumberland, one of the largest undeveloped Carlin-style gold
 deposits; Long Canyon, a discovery defining a new gold trend; and,
 Sandman, a property Newmont Mining Corp. has the option of advancing
 to a production decision within 36 months. In Turkey, Fronteer has a
 40% interest in a new mineral district that includes two gold
 deposits and a copper-gold porphyry deposit. Fronteer has no debt
 and holds approximately C$85 million in cash that is fully liquid
 and held with a large Canadian bank.
Company: FX Energy, Inc.
Ticker Symbol & Exchange: FXEN
Investor Relations Contact: Scott Duncan
Investor Relations Contact
 Phone: 801 486-5555
Web: www.fxenergy.com
Date of Presentation: 11/11/2008
We are an independent oil and gas exploration and production company
 headquartered in Salt Lake City, Utah. Our principal production,
 reserves, and exploration activities are in Poland, although we have
 a modest oil presence in the U.S. We hold 3.7 million gross acres
 (3.2 million net) in Poland. We believe Poland represents a unique
 international exploration opportunity. Relatively little gas has
 been discovered in Poland's sector of the North European Permian
 Basin, compared to the discoveries in the United Kingdom, Dutch, and
 German sectors. Consequently, we think the Polish Permian Basin is
 underexplored and underexploited.
Company: Gastar Exploration Ltd.
Ticker Symbol & Exchange: AMEX:GST/TSX:YGA
Investor Relations Contact: Michael Gerlich
Investor Relations Contact
 Phone: 713-739-1800
Web: www.gastar.com
Date of Presentation: 11/12/2008
Gastar has significant acreage in the Deep Bossier Sands play in East
 Texas, the developing Marcellus Shale play in Appalachia, the Powder
 River Basin, and the Gunnedah Basin of southeastern Australia. In
 East Texas, Gastar controls approximately 15,350 net acres in Leon
 and Robertson counties. Since 2003, Gastar has successfully
 completed 16 Bossier and five Knowles wells. We are currently
 running a two-rig program to drill offsets to recent successful
 Bossier wells. In Australia, coalbed methane development programs
 are under way on 2.1 million net acres to supply developing gas
 markets in New South Wales. In Appalachia, we are pursuing
 development of shale gas beneath approximately 42,000 net acres of
 leases in West Virginia and Pennsylvania near acreage held by the
 most active participants in the play.
Company: Genco Resources Ltd.
Ticker Symbol & Exchange: TSX: GGC
Investor Relations Contact: Ms. Jada Soomer
Investor Relations Contact
 Phone: (604) 682-2205
Web: www.gencoresources.com
Date of Presentation: 430pm - 455pm November 10th
Genco Resources Ltd. is a publicly-traded mining company focused on
 developing its La Guitarra silver property in Mexico.
Genco's core asset, the producing La Guitarra silver-gold mine, is
 located in the Temascaltepec Mining District of Mexico. La Guitarra
 Mine currently consists of two underground operation centres - La
 Guitarra and San Raphael - and a flotation mill with a proven
 capacity of 320 tonnes per day. Genco believes significant potential
 exists to expand production within the 39,714 hectares of mining
 concessions it currently owns or leases in the Temascaltepec Mining
 District.
Genco aims to create solid shareholder value through continued growth
 and increased production.
Company: Glass Earth Gold Ltd
Ticker Symbol & Exchange: GEL: TSXV
Investor Relations Contact: Lindsay Carpenter
Investor Relations Contact [email protected], 416-868-1079 ext.
 Phone: 239
Web: www.glassearthlimited.com
Date of Presentation: 11/11/2008
Glass Earth is a New Zealand based gold explorer with the largest on-
 shore gold exploration permit portfolio (over 22,000 square
 kilometers). Glass Earth's strategy is to apply sophisticated use of
 new technology, over entire geological provinces permissive for
 large gold deposits. Glass Earth is now at the target specific
 drilling stage in 3 regions: Hauraki; Mamaku and Otago. Glass
 Earth's strategy for 2008/2009 is to continue work on high priority
 targets, building towards 43 101 compliant resources. Glass Earth
 has over $2.2 million cash and 3 contributory joint ventures,
 including 2 with Newmont over the Hauraki Region and an area next to
 Newmont's Martha Gold Mine.
Company: Gold Horse International, Inc.
Ticker Symbol & Exchange: GHII
Investor Relations Contact: Adam Wasserman
Investor Relations Contact (800)867-0078 Ext. 702
 Phone:
Date of Presentation: 3:15 p.m. 12th November 2008
Gold Horse International, Inc., through its wholly owned
 subsidiaries, Gold Horse International, Inc. (Nevada) and Global
 Rise International Ltd., controls and operates Inner Mongolia Jin Ma
 Construction Co., Ltd., Inner Mongolia Jin Ma Hotel Co., Ltd., and
 Inner Mongolia Jin Ma Real Estate Development Co., Ltd., all based
 in Hohhot, the regional capital of Inner Mongolia Autonomous Region
 in China. Jin Ma Construction has been providing construction and
 general contractor services in Hohhot to both private developers and
 to the local and regional governments since 1980. Jin Ma Hotel owns,
 operates and manages the Jin Ma Hotel, a full-service, two-star
 hotel located in Hohhot. Jin Ma Real Estate develops residential and
 commercial properties in Hohhot.
Company: GTC Biotherapeutics
Ticker Symbol & Exchange: GTCB
Investor Relations Contact: Thomas Newberry
Investor Relations Contact
 Phone: 508-370-5374
Web: www.gtc-bio.com
Date of Presentation: 11/11/2008
GTC Biotherapeutics develops, supplies, and commercializes
 therapeutic proteins produced through transgenic animal technology.
 ATryn(R), GTC's recombinant human antithrombin, has been approved
 for use in Europe and is being reviewed in the United States under a
 Biologics License Application. In addition to ATryn(R), GTC is
 developing a portfolio of recombinant human plasma proteins with
 known therapeutic properties. GTC also has a monoclonal antibody
 portfolio that includes a monoclonal antibody to CD20 as well as to
 CD137. GTC's transgenic production platform is particularly well
 suited to enabling cost effective development of proteins that are
 difficult to express in traditional recombinant production systems
 as well as those that are required in large volumes.
Company: Gulf Resources, Inc.
Ticker Symbol & Exchange: GFRE.OB
Investor Relations Contact: Crocker Coulson
Investor Relations Contact
 Phone: 646-213-1915
Web: www.gulfresourcesco.com
Date of Presentation: 10:45AM, ET, November 10, 2008
Gulf Resources, Inc. is a leading provider of chemical products in
 the People's Republic of China. The Company operates through its two
 wholly-owned subsidiaries; Shouguang City Haoyuan Chemical Company
 Limited (SCHC), which primarily produces and distributes bromine and
 crude salt, and Shouguang Yuxin Chemical Industry Co., Limited
 (SYCI), which focuses on manufacturing and selling chemical
 products. Elemental bromine is used to manufacture a wide range of
 compounds utilized in manufacturing industries and in agriculture.
 The Company's chemical products are utilized in a variety of
 applications, including oil and gas field exploration, and as
 papermaking chemical agents.
Company: Hollis-Eden Pharmaceuticals, Inc.
Ticker Symbol & Exchange: NASDAQ: HEPH
Investor Relations Contact: Scott A. Rieger
Investor Relations Contact
 Phone: 858-587-9333
Web: www.holliseden.com
Date of Presentation: 11/10/2008
Hollis-Eden Pharmaceuticals is developing a proprietary new class of
 small molecule compounds that are metabolites or synthetic analogs
 of adrenal steroid hormones. The Company's clinical drug development
 candidates include TRIOLEX(TM) (HE3286), currently in clinical
 trials for the treatment of type 2 diabetes, ulcerative colitis and
 rheumatoid arthritis, and APOPTONE(TM) (HE3235), in a clinical trial
 for late-stage prostate cancer. In addition to these drug
 candidates, designed to restore the biological activity of cellular
 signaling pathways disrupted by disease and aging, Hollis-Eden has
 an active research program generating additional compounds that are
 being evaluated in preclinical models of a number of diseases.
Company: Hong Kong Highpower Technology, Inc.
Ticker Symbol & Exchange: Amex: HPJ
Investor Relations Contact: Brandi Floberg
Investor Relations Contact
 Phone: 310-277-4711
Web: http://www.haopengbattery.com/
Date of Presentation: November 12, 2008 at 2:00 p.m. ET
Hong Kong Highpower Technology is a profitable growth company that
 develops, manufactures and markets nickel-metal hydride (Ni-MH) and
 lithium-ion (Li-ion) rechargeable batteries and related products for
 consumer and industrial applications. The Company's products are
 distributed worldwide for use in various electronic products and
 emergency power supplies such as digital and communication products,
 power tools, toys, notebook computers, cell phones, GPS navigation
 systems, military products, electronic bikes and medical devices.
 The Company's manufacturing and product development facilities are
 located in Shenzhen, Guangdong Province, PRC, which facilitates low
 labor costs and easy access to land and raw materials, as well as
 additional cost and cycle time advantages garnered by proximity to
 electronics supply chains and end-markets.
Company: Horizon Therapeutics
Investor Relations Contact: Bob DeVaere
Investor Relations Contact
 Phone: 760-436-4010
Web: www.horizontherapeutics.com
Date of Presentation: 11/12/2008
Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company
 focused on the development and commercialization of therapies for
 the treatment of mild-to-moderate pain and arthritis. Horizon's
 clinical portfolio includes innovative combination therapies in
 early- and late-stage development that are designed to improve
 safety, efficacy and patient compliance.
Horizon's lead compound is HZT-501, a novel, proprietary, fixed-dose
 combination formulation of the world's most prescribed non-steroidal
 anti-inflammatory drug (NSAID), ibuprofen, with a high dose of the
 most potent H2 antagonist, famotidine (Pepcid), in a single
 pillwhich
For more information about the company and its products, please visit
 www.horizontherapeutics.com.
Company: Hudson Technologies
Ticker Symbol & Exchange: HDSN; NASDAQ
Investor Relations Contact John Nesbett, 203-972-9200
 Phone:
Web: www.hudsontech.com
Date of Presentation: 11/10/2008
Hudson Technologies is a leading provider of refrigerants and the
 largest reclaimer in the U.S. for commercial refrigeration and air
 conditioning systems. In addition to its refrigerant sales and
 reclamation business, Hudson also provides energy optimization of
 large steam and refrigeration systems as well as energy efficiency
 assessments. The company's two revenue streams are:
Refrigerant Product Services (RPS), comprised of refrigerant sales
 and reclamation of refrigerants, such as CFCs, HCFCs and replacement
 refrigerants used in commercial air conditioning and refrigeration
 systems.
RefrigerantSide(R) Services (R-Side(R)) identifies and provides
 predictive and emergency solutions for mechanical and chemical
 issues in large process and comfort cooling systems.
Company: Hythiam, Inc.
Ticker Symbol & Exchange: HYTM/NASDAQ
Investor Relations Contact: Hasmik Bulujian
Investor Relations Contact [email protected], 310-444-4333
 Phone:
Web: www.hythiam.com
Date of Presentation: Monday, November 10, 2008
Hythiam provides through its Catasys offering, behavioral health
 management services to health plans, employers and unions through
 licensed and company managed healthcare providers. Catasys offers
 integrated substance dependence solutions built around the patented
 PROMETA Treatment Program for alcoholism and stimulant dependence.
 PROMETA, which integrates behavioral, nutritional, and medical
 components, is also available on a private-pay basis through
 licensed treatment providers and company managed treatment centers.
 Hythiam researches, develops, licenses and commercializes innovative
 and proprietary physiological, nutritional, and behavioral treatment
 programs. Hythiam does not manufacture, distribute, or sell any
 medications and has no relationship with any
 manufacturers/distributors of medications used in the PROMETA
 Treatment Program.
Company: ICP Solar Technologies
Ticker Symbol & Exchange: OTC BB: ICPR
Investor Relations Contact: Chris Witty
Investor Relations Contact
 Phone: 646-438-9385
Web: www.ICPSolar.com
Date of Presentation: 11/10/2008
ICP Solar is a developer, manufacturer and marketer of solar panels,
 solar cell based products, solar monitoring software and solar power
 management solutions. Through the application of its own
 intellectual property and next-generation technologies, the Company
 aims to be the solar industry's innovation leader. For the past 20
 years, ICP Solar has been a lead innovator in the consumer solar
 market and has now begun to apply that same innovation philosophy to
 the OEM, rooftop and power generation segment of the solar industry.
 ICP Solar's management has over 50 years of experience in the
 renewable energy sector. ICP Solar markets its products under its
 Sunsei(R) brand of solar products and is the North American licensee
 of the Coleman(R) brand in the solar charger category.
Company: ImmunoCellular Therapeutics
Ticker Symbol & Exchange: OTCBB:IMUC
Investor Relations Contact: Jennifer Cook Williams
Investor Relations Contact
 Phone: 360-668-3701
Web: www.imuc.com
Date of Presentation: 11/11/2008
ImmunoCellular Therapeutics is a Los Angeles-based clinical-stage
 company that is developing immune based therapies for the treatment
 of brain and other cancers. IMUC's lead product candidate--a
 dendritic cell-based vaccine for treating brain tumors--is currently
 being evaluated in a Phase I clinical trial. The company's "off the
 shelf" therapeutic vaccine product candidate targeting cancer stem
 cells for multiple cancer indications is expected to enter clinical
 trials during the first half of 2009. IMUC is in pre-clinical
 development of a monoclonal antibody product candidate for the
 treatment of small cell lung cancer and pancreatic cancer.
Company: ImmuneRegen BioSciences, Inc
Ticker Symbol & Exchange: IRBS OTCBB
Investor Relations Contact: John Fermanis
Investor Relations Contact
 Phone: 480-322-3926
Web: www.immuneregen.com
Date of Presentation: November 10, 2008 12:25pm
ImmuneRegen BioSciences, Inc. (OTCBB: IRBS) is a development-stage
 biotechnology company focused on the research, development and
 licensing of Homspera(R), an adult stem cell active peptide that
 regenerates and strengthens the immune system and enhances wound
 healing. Homspera's ability to enhance adult stem cell activity in
 bone marrow underlies the successful animal studies we've reported
 previously for the compound in the areas of protection from lethal
 radiation, treating neutropenia, vaccine adjuvancy, infectious
 disease (both alone and in combination) and wound healing. We've
 forged numerous partnerships with both industry and academic leaders
 as we progress toward IND filing planned for mid-2009.
Company: Industrea Limited
Ticker Symbol & Exchange: ASX: IDL
Investor Relations Contact: Jennifer K. Zimmons, Ph.D.
Investor Relations Contact
 Phone: 212-838-1444
Web: www.industrea.com.au
Date of Presentation: Tuesday, Nov. 11, 2008 9:55am
Industrea Limited (ASX: IDL) manufactures, sells and supports market-
 leading mining products globally and provides integrated contract-
 mining services. Industrea's business provides diversified revenue
 streams arising from mining, asset management, and engineering
 services. The Company's geographical footprint includes: Australia,
 United States, South America, Indonesia, New Guinea, Russia, and
 China. Major customers include: BHP, Anglo Coal, Rio Tinto and
 Xstrata. Industrea continues to expand its markets, range of
 products and services, and customers to increase the Company's
 sources of revenue. Current mining products include: collision-
 avoidance systems, underground directional-drilling, above-ground
 directional drilling, contractor management, mobile-asset tracking
 and driver-safety performance index.
Company: InNexus Biotechnology Inc.
Ticker Symbol & Exchange: (TSX: IXS.V) (IXSBF.OB)
Investor Relations Contact: Jeff Morhet
Investor Relations Contact
 Phone: 480-862-7500
Web: www.ixsbio.com
Date of Presentation: November 11, 2008 at 12:00 p.m.
InNexus is a drug development company commercializing the next
 generation of monoclonal antibodies based on its DXL(TM) technology,
 which improves the potency of existing antibody products while
 opening new markets and disease applications.
In a short period of time, InNexus has assembled facilities,
 resources, a stellar Scientific Advisory Board, staff and milestones
 yielding multiple pre-clinical candidates targeting cancer and other
 commercial opportunities. InNexus has launched into pre-clinical
 development its first four products, DXL625 and DXLr120, both for
 the prospective treatment of non-Hodgkin's lymphoma and other immune
 disorders that include rheumatoid arthritis, DXL702 for the
 treatment of breast cancer and DXL1215 targeting endometriosis.
Company: Inovio Biomedical Corporation
Ticker Symbol & Exchange: INO - AMEX
Investor Relations Contact: Bernie Hertel
Investor Relations Contact
 Phone: 858 410 3101
Web: www.inovio.com
Date of Presentation: 11/10/2008
Inovio Biomedical is focused on developing DNA vaccines for cancers
 and infectious diseases using its novel method for DNA delivery -
 electroporation - which uses brief, controlled electrical pulses to
 increase cellular uptake of useful biopharmaceuticals. Initial human
 data has shown that Inovio's electroporation delivery technology can
 significantly increase gene expression and immune responses from DNA
 vaccines. Immunotherapy partners include Merck, Wyeth, Vical,
 Tripep, University of Southampton, Moffitt Cancer Center, the U.S.
 Army, National Cancer Institute, and International Aids Vaccine
 Initiative. Inovio is also conducting proprietary vaccine R&D. The
 company's technology is protected by an extensive patent portfolio
 covering in vivo electroporation.
Company: InterAmerican Acquisition Group Inc.
Ticker Symbol & Exchange: IAQG.OB, OTCBB
Investor Relations Contact: Mr. Crocker Coulson
Investor Relations Contact
 Phone: 646-213-1915
Web: www.cncdev.com
Date of Presentation: Wednesday, November 12, 2008
InterAmerican Acquisition Group Inc. raised $46 million in a Sept.
 2007 IPO and recently announced plans to acquire Sing Kung, Ltd. The
 combined company, China New Cities Development Ltd. ("CNC") will
 continue to deliver comprehensive planning and infrastructure build-
 outs to selected municipalities throughout China. CNC's "Build-
 Transfer" business model allows local governments to overcome
 financial and project management constraints and to quickly unlock
 economic development potential and property value. CNC employs
 unique capabilities and exceptional strategic relationships to
 deliver turnkey solutions to progressive cities that are expanding
 or redeveloping urban cores to meet explosive growth. CNC is
 profitable (34% pre-tax 1st half) and growing rapidly, driven by
 strong macroeconomic and demographic factors in China.
Company: Interleukin Genetics, Inc.
Ticker Symbol & Exchange: AMEX: ILI
Investor Relations Contact: Melanie Friedman
Investor Relations Contact
 Phone: 212-362-1200
Web: http://www.ilgenetics.com
Date of Presentation: 11/10/2008
Interleukin Genetics is a leading, genetics-focused personalized
 health company developing preventive consumer products and genetic
 tests for the emerging personalized health market. Interleukin uses
 its leading genetics research and scientific capabilities to develop
 and test innovative preventive and therapeutic products. Interleukin
 has commercialized several genetic tests: the PST(R) Periodontal
 genetic test, the Gensona(R) IL-1 Cardiovascular genetic test and
 the Gensona(R) General Nutrition genetic test. Interleukin is
 developing additional genetic tests to address significant health
 risks for osteoporosis, obesity, arthritis and cancer. Interleukin
 also offers an array of Nutraceuticals which are sold at the
 nation's largest food, drug and mass retailers.
Company: International Montoro Resources
Ticker Symbol & Exchange: TSX-V: IMT
Investor Relations Contact: Christopher Haldane
Investor Relations Contact 416.868.1079 ex.237
 Phone:
Web: www.montororesources.com
Date of Presentation: 11/11/2008
International Montoro Resources is charging forward in the cleaner
 energy world of tomorrow. Montoro is currently advancing uranium
 projects in the world's powerhouse region for Uranium - Saskatchewan
 (Crackingstone/Orbit-Uranium City) and Ontario (Elliot Lake)-once
 known as the Uranium Capital of the World. While many uranium
 companies are spending their investment dollars in one province or
 region, Montoro and its joint venture partners are currently
 advancing two projects in two separate regions, managing the risk
 for their investors to maximize potential in becoming a "True North"
 cleaner and greener uranium mining company.
Company: Iteris, Inc.
Ticker Symbol & Exchange: ITI (AMEX)
Investor Relations Contact: Brett Maas
Investor Relations Contact
 Phone: 646-536-7331
Web: www.iteris.com
Date of Presentation: 11/10/2008
Iteris, Inc. is a leader in the traffic management market focused on
 the development and application of advanced technologies that reduce
 traffic congestion, minimize the environmental impact of traffic
 congestion and improve the safety of surface transportation systems.
 Combining outdoor image processing, traffic engineering and
 information technology, Iteris offers a broad range of Intelligent
 Transportation Systems and driver safety solutions to customers
 worldwide. Iteris is headquartered in Santa Ana, California with
 offices throughout the U.S., Europe, and Asia. Investors are
 encouraged to contact us at 888-329-4483, or at www.iteris.com.
Company: Javelin Pharmaceuticals, Inc.
Ticker Symbol & Exchange: AMEX: JAV
Investor Relations Contact: Rick Pierce
Investor Relations Contact
 Phone: 617-499-4703
Web: www.javelinpharma.com
Date of Presentation: 11/10/2008
Javelin Pharmaceuticals, Inc. is a specialty pharmaceutical company
 that develops and markets innovative proprietary products to treat
 acute moderate-to-severe pain in medically supervised settings. The
 company's product candidates offer faster relief of pain, with
 potentially fewer adverse side effects compared to other currently
 available treatments. Javelin seeks to reduce development risk and
 maximize commercial opportunity through novel administration routes,
 novel formulations and new labeling for existing FDA approved active
 pharmaceutical ingredients. The company's product candidates also
 enjoy robust global patent protection.
Company: Jennerex, Inc.
Investor Relations Contact: Ian Malone
Investor Relations Contact
 Phone: 613-730-8019
Web: www.jennerex.com
Date of Presentation: 11/11/2008
Jennerex is a clinical-stage biopharmaceutical company focused on the
 development and commercialization of first-in-class, breakthrough
 targeted oncolytic products for cancer. The company's lead product
 JX-594, currently in an international Phase 2 trial for primary
 liver cancer, demonstrated promising Phase 1 efficacy and safety
 results in patients with a diverse array of common large market
 cancers. Jennerex's products target, attack and eradicate cancers
 through a novel and potent oncolytic mechanism that is dependent on
 highly-specific replication of the company's poxviruses in cancer
 cells. These products simultaneously stimulate the body's immune
 response to the cancer. Of note, this mechanism of action and the
 results in patients to date put the company's product class in a
 leadership position.
Company: Jingwei International Limited
Ticker Symbol & Exchange: JNGW
Investor Relations Contact: Regis Kwong
Investor Relations Contact
 Phone: 86-10-85885690
Web: www.jingweicom.com
Date of Presentation: November 10th
Jingwei International Limited has evolved into an integrated
 marketing services provider, powered by its consumer database and
 data mining capabilities. The Company is known as one of the leaders
 in providing direct marketing services to global companies doing
 business in China. Jingwei's proprietary data base of over 300M
 Chinese consumers as well as its real time analysis tools, enable
 its customers to create and manage their advertising content and
 monitor results, while improving immediately ROI. In addition, the
 Company has a geographic presence in 20 cities throughout China and
 an executive and technical team that has global experience in the
 direct marketing space. As multinational and domestic companies in
 China increase their penetration of the rapidly expanding Chinese
 market they seek to reach the appropriate targeted audience
Company: Kinbauri Gold Corp.
Ticker Symbol & Exchange: KNB (TSXV)
Investor Relations Contact Darrell Munro 613-836-0198
 Phone:
Web: www.kinbauri-gold.com
Date of Presentation: November 11
Kinbauri is a TSX Mineral Exploration Company focused on the
 development of mineral properties, primarily precious metal
 prospects in northwestern Spain. Its immediate focus is to expand
 and upgrade resources to reserves at the El Valle property in
 Asturias, Spain in order to start operations at the mine and
 existing mill complex there in 2010.
Kinbauri To Become Western Europe's Largest Gold Producer
Current Resources stand at 2.2M ounces of gold and 157 Million Pounds
 of Copper. Kinbauri has over $100M of infrastructure on site
 including a fully operational Mill and is targeting production of
 145,000 ounces of gold equivalent per year.
Company: Kodiak Exploration Limited
Ticker Symbol & Exchange: TSXV:KXL
Investor Relations Contact: Brian Maher, Bill Chornobay
Investor Relations Contact
 Phone: 1-888-688-9006
Web: www.kodiakexp.com
Date of Presentation: Tuesday November 11, 2008
Kodiak Exploration Limited is an excellent exploration company with a
 new high-grade gold discovery in the Beardmore-Geraldton gold camp
 in Ontario, Canada. The Golden Mile was recently recognized by
 industry peers as Discovery of the Year. Kodiak controls the
 majority of this underexplored gold camp, and is simultaneously
 exploring numerous other stand-alone targets. With excellent
 infrastructure, experienced management, $40 million cash, and no
 debt, Kodiak enjoys very strong institutional support, and is on
 track to achieve its short and long term objectives. On October 30,
 Kodiak was rated Outperform at $4 by National Bank Financial.
Company: Labrador Iron Mines Holdings Limited
Ticker Symbol & Exchange: TSX:LIR
Investor Relations Contact: John F. Kearney
Investor Relations Contact John F. Kearney, (647)728-4125
 Phone:
Web: www.labradorironmines.ca
Date of Presentation: 11/10/2008
Labrador Iron Mines Holdings Limited is developing "direct shipping"
 iron ore deposits in the Labrador Trough, in the province of
 Newfoundland and Labrador, near Schefferville, Quebec, Canada.
The Company was listed on the TSX in December 2007, following a
 successful IPO in which it raised over $52 million.
Over 150 million tons of direct shipping iron ore was previously
 mined by the Iron Ore Company from 1954 to 1982.
LIM's operations will utilize much of the existing infrastructure
 constructed for the former operations. Mining will be open pit
 methods and broken ore will be screened and washed to upgrade iron
 content prior to rail shipment.
Labrador Iron Mines is targeting to commence production of both lump
 and sinter fine ore in 2009.
Company: Laurion Mineral Exploration Inc.
Ticker Symbol & Exchange: TSXV: LME
Investor Relations Contact: CHF Investor Relations
Investor Relations Contact Jacqueline Wagenaar, (416) 868-1079
 Phone: x289
Web: www.laurion.ca
Date of Presentation: November 11th, 2008 at 11:10am
Laurion Mineral Exploration Inc. is an exploration stage company
 engaged in the acquisition, exploration and development of its
 highly prospective base metals, platinum group elements (PGEs) and
 gold properties in Northern Ontario. In addition, Laurion is
 aggressively pursuing the acquisition of advanced exploration
 properties that are near to production either locally or
 internationally.
Laurion's flagship property the Sturgeon River Project, which has
 received numerous market interest, is a past producing gold project
 located in the Geraldton-Beardmore Gold Camp which has reportedly
 produced more than 4.12M ounces since 1925.
Company: Lectus Therapeutics Limited
Investor Relations Contact: Roland Kozlowski, CEO
Investor Relations Contact
 Phone: 44 (0)1223 499050
Web: www.lectustherapeutics.com
Date of Presentation: November 12th
Lectus Therapeutics Limited is a Cambridge (UK)-based pharmaceutical
 company. Its mission is to build a development pipeline containing
 first-in-class ion channel therapeutics for pain management and
 related indications.
Lectus exploits the power of its proprietary functional proteomics
 platform, LEPTICS(R), and builds on its knowledge of ion channels
 and protein-protein interactions, to identify and develop next-
 generation channel modulators that offer desirable clinical profiles
 with commensurate economic advantages.
Lectus has attracted a top tier syndicate of investors (including
 Sofinnova Partners, Spark Ventures, Takeda Research Investment and
 Astellas Venture Management) to support advancement of the company's
 existing discovery programmes.
Company: LightPath Technologies, Inc.
Ticker Symbol & Exchange: NASDAQ: LPTH
Investor Relations Contact: Mark McPartland
Investor Relations Contact
 Phone: (910) 221-1827
Web: www.lightpath.com
Date of Presentation: Monday, November 10th at 3:40 p.m.
LightPath manufactures optical products including precision molded
 aspheric optics, GRADIUM(R) glass products, proprietary collimator
 assemblies, laser components utilizing proprietary automation
 technology, higher-level assemblies and packing solutions. LightPath
 has a strong patent portfolio that has been granted or licensed to
 us in these fields. LightPath common stock trades on The Nasdaq
 Capital Market under the stock symbol LPTH. For more information
 visit www.lightpath.com
Company: Medgenics
Ticker Symbol & Exchange: (AIM: MEDG)
Investor Relations Contact: Leslie Wolf-Creutzfeldt
Investor Relations Contact
 Phone: (646) 284-9472
Web: http://www.medgenics.com
Date of Presentation: 11/12/2008
Medgenics, Inc. is a clinical-stage biopharmaceutical company
 developing its unique tissue-based Biopump platform technology to
 provide sustained-action protein therapy for the treatment of a
 range of chronic diseases.
Medgenics currently has two products in development based on this
 technology:
EPODURE - producing erythropoietin (EPO) to treat anaemia
INFRADURE - producing interferon-alpha (IFN-alpha) to treat hepatitis
 C
The Company has demonstrated proof of principle of the Biopump
 treatment procedure in a clinical trial using a short-acting version
 of EPODURE in anemic subjects. The Company commenced a Phase I/II
 clinical trial for its long-acting version of EPODURE, designed to
 produce and deliver a therapeutic dose of EPO steadily for three to
 six months or more, in August 2008.
Company: Medivir AB
Ticker Symbol & Exchange: OME: MVIRB SS
Investor Relations Contact: Mr Rein Piir
Investor Relations Contact
 Phone: 46 708 53 72 92
Web: www.medivir.com
Date of Presentation: 11/12/2008
Medivir develops pharmaceuticals and has several collaborations with
 established pharmaceutical companies as well as smaller biotech
 enterprises.
The majority of our projects are based on developing protease
 inhibitors into innovative drugs and we have a strong commitment in
 the development of hepatitis C pharmaceuticals.
In clinical development phase there is one investigational drug
 against labial herpes were Medivir recently filed an NDA in both USA
 and Europe. Two projects target HCV; TMC435350 in clinical phase II
 and the other in preclinical development phase. Furthermore there
 are three projects in phase II and two in phase I and several
 protease projects in late preclinical stage.
Company: Midnight Oil Exploration Ltd.
Ticker Symbol & Exchange: MOX: TSX
Investor Relations Contact: Jo Ellen Krchnak
Investor Relations Contact
 Phone: 403-303-8510
Web: www.midnightoil.ca
Date of Presentation: 11/10/2008
Midnight is a top quality junior exploration and production company
 that focuses on the selected multi-zone, high potential areas of the
 Western Canadian Sedimentary Basin. Midnight employs a proven
 formula combining a high-end technical team with experience,
 expertise, and innovative operational and business execution skills
 to provide a competitive edge in our areas of operation. Midnight is
 an active practitioner of the latest technical advances in geology,
 geophysics, reservoir engineering, drilling and completions and has
 recently acquired a large holding on a tight gas resource play
 within the sweet spot of the Deep Basin at Elmworth and Wapiti.
Company: MiMedx Group, Inc.
Ticker Symbol & Exchange: OTCBB: MDXG
Investor Relations Contact: John Thomas
Investor Relations Contact
 Phone: 770-514-0077
Web: www.mimedx.com
Date of Presentation: 11/10/2008
MiMedx Group, Inc., (MDXG) is an integrated developer, manufacturer,
 and marketer of patent protected, spine and orthopedic implants
 which represent breakthroughs in the treatment of trauma and
 disease. The company is positioned for rapid growth in revenues and
 profits.
Utilizing novel materials and techniques, our products are implants
 intended to competitively address a broad range of acute and chronic
 musculoskeletal diseases and disorders in the spine, orthopedic, and
 general surgery marketplace.
The markets for the specific indications our products address is
 estimated at over $7.5 billion* and projected to grow at a compound
 annual rate of greater than 20% a year through 2025.
Company: Molecular Insight Pharmaceuticals,
 Inc.
Ticker Symbol & Exchange: NASDAQ: MIPI
Investor Relations Contact: Deborah S. Lorenz
Investor Relations Contact
 Phone: 617-492-5554
Web: www.molecularinsight.com
Date of Presentation: 11/12/2008
Molecular Insight Pharmaceuticals, Inc. is a biopharmaceutical
 company specializing in the emerging field of molecular medicine,
 applying innovations in the identification and targeting of disease
 at the molecular level to improve healthcare for patients with life-
 threatening diseases. The Company is focused on discovering,
 developing and commercializing innovative molecular imaging
 radiopharmaceuticals and targeted molecular radiotherapeutics with
 initial applications in the areas of cardiology and oncology.
Company: Momenta Pharmaceuticals, Inc.
Ticker Symbol & Exchange: MNTA - NASDAQ
Investor Relations Contact: Beverly Holley
Investor Relations Contact
 Phone: 617-395-5189
Web: www.momentapharma.com
Date of Presentation: November 11th, 12:25pm
Momenta Pharmaceuticals leverages its proprietary technology to
 unlock the structural secrets of complex sugars and other complex
 mixtures. Our unique tools and approach to drug development have
 yielded a diversified product pipeline consisting of technology-
 enabled generic drugs, re-engineered drugs and novel drug
 candidates.
Company: MorphoSys AG
Ticker Symbol & Exchange: FSE (Germany): MOR
Investor Relations Contact: Ms. Claudia Gutjahr
Investor Relations Contact
 Phone: +49 (89) 899 27-404
Web: www.morphosys.com
Date of Presentation: Nov. 11th, 2008
MorphoSys AG, located in Martinsried/Munich (Germany), is one of the
 world's leading biotechnology companies focusing on fully human
 antibodies. With its unique technologies, MorphoSys is developing
 the next generation of antibodies, which can be used to treat
 diseases and for research and diagnostics purposes. Numerous
 partnerships have already been entered into with well-known
 companies, such as Merck&Co, Novartis, Pfizer, and Roche.
The Company possesses the unique HuCAL technology (the Human
 Combinatorial Antibody Library). This library comprises more than
 ten billion different, fully human antibodies. HuCAL is a very
 powerful technology, which allows rapid and automated production of
 high-affinity antibodies.
Company: Morria Biopharmaceuticals Plc
Investor Relations Contact: Yuval Cohen
Investor Relations Contact
 Phone: 917-361-5210
Web: www.morria.com
Date of Presentation: Nov 10: from 10:45 to 11:10 AM
Morria Biopharmaceuticals Plc (founded 2005) is focused on the
 development of novel, non-steroidal anti-inflammatory drugs. Lead
 products are first-in-class, synthetic drugs termed Multi-Functional
 Anti-Inflammatory Drugs (MFAID). These unique drugs target a known
 but previously elusive key event in the inflammation process
 upstream of current competitors while simultaneously protecting
 cells and tissues against inflammatory damage. Morria has two lead
 products in clinical development MRX-4 (allergic rhinitis, Phase II)
 and MRX-6 (contact dermatitis, Phase II) and a growing library of
 additional compounds targeting IBD, ophthalmology and cystic
 fibrosis. To-date, this private company has raised $7m and is
 preparing for a round C of $10m-$15m.
Company: Neotropix Inc.
Investor Relations Contact: LaVoie Group
Investor Relations Contact Lisa Rivero, 617-947-0899
 Phone:
Web: Neotropix.com
Date of Presentation: November 10, 2008 4:55 PM Louis Roo
Neotropix began operations in 2005 to develop and commercialize
 naturally derived, systemically deliverable oncolytic viruses for
 the treatment of solid tumors. The company has brought three of the
 candidates into pre-clinical testing one of which (NTX-010) is in a
 large US phase I/II study being conducted at 11 sites testing the
 drug over a range of neuroendocrine cancers at various doses. The
 Phase I/II trial is expected to complete enrollment in Q4 2008 with
 full data disclosure in 2009. Additionally, the company is planning
 a phase II/III trial in Small Cell Lung Cancer based upon the
 results observed in the Phase I/II
Company: NetSol Technologies
Ticker Symbol & Exchange: (NASDAQ:NTWK)
Investor Relations Contact: Christopher Chu
Investor Relations Contact
 Phone: 646-284-9426
Web: www.netsoltech.com
Date of Presentation: 11/10/2008
NetSol Technologies is a U.S. corporation providing global business
 services and enterprise application solutions to private and public
 sector organizations worldwide. NetSol uses its BestShoring(TM)
 practices and highly experienced resources in analysis, development,
 quality assurance, and implementation to deliver high-quality, cost-
 effective solutions. Organized into specialized industries, these
 product and services offerings include portfolio management systems
 for the financial services industry, consulting, custom development,
 systems integration, and technical services for the global
 healthcare, insurance, real estate, and technology markets.
Company: Neuralstem, Inc.
Ticker Symbol & Exchange: Amex: CUR
Investor Relations Contact: Steve Chizzik
Investor Relations Contact
 Phone: 908-688-9111
Web: www.neuralstem.com
Date of Presentation: Monday, November 10, 2008
Neuralstem targets Major Central Nervous System diseases with its
 patented stem cell technology. Research programs currently underway
 include: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury
 and ALS. The company's cells have extended the life of rats with ALS
 (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in
 collaboration with Johns Hopkins University researchers, and also
 reversed paralysis in rats with Ischemic Spastic Paraplegia, as
 reported in NEUROSCIENCE in June 2007, in collaboration with
 researchers at University of California San Diego. The Company
 expects to file its first IND (Investigational New Drug) application
 with the FDA for ALS in the near future.
Company: Nevsun Resources
Ticker Symbol & Exchange: NSU on TSX and AMEX
Investor Relations Contact: John Clarke
Investor Relations Contact
 Phone: 604 623 4700
Web: nevsun.com
Date of Presentation: 11/12/2008
Nevsun Resources Ltd. is a TSX/AMEX listed junior focused on
 developing gold & base metals projects in Africa.
Nevsun's Bisha Mine in Eritrea will be a low cost gold producer for
 its first two years of production (approx. 430,000 ounces gold per
 year) and a low cost high grade copper concentrate producer
 (containing approx. 75,500 tonnes of contained copper metal per
 year) for a further three years. Thereafter the mine will produce
 separate zinc and copper concentrates.
Company: NGAS Resources, Inc.
Ticker Symbol & Exchange: NGAS
Investor Relations Contact: Kathleen Heaney
Investor Relations Contact
 Phone: 203-803-3585
Web: www.ngas.com
Date of Presentation: Wed., Nov. 12, 2008, 11:10 a.m. (E)
NGAS (Nasdaq: NGAS) is an Exploration & Production company focused on
 unconventional natural gas plays in the eastern U.S., primarily in
 the southern portions of the Appalachian and Illinois Basins. The
 company has specialized in generating and developing geological
 prospects for over 20 years.
NGAS holds 366,000 acres of oil and gas leases for development, owns
 interests in over 1,300 wells, and 636 miles of gas gathering
 pipeline. Ninety percent of the company's southern Appalachian gas
 production is delivered directly from the wellhead to the interstate
 gas transportation system.
Company: Novelos Therapeutics, Inc.
Ticker Symbol & Exchange: OTCBB: NVLT
Investor Relations Contact: Stephen Lichaw
Investor Relations Contact
 Phone: 201-240-3200
Web: www.novelos.com
Date of Presentation: November 10, 2008, 10:45am
Novelos Therapeutics, Inc. is a biopharmaceutical company
 commercializing oxidized glutathione-based compounds for the
 treatment of cancer and hepatitis. NOV-002, the lead compound
 currently in Phase 3 development for lung cancer under SPA and Fast
 Track, acts together with chemotherapy as a chemoprotectant and a
 chemopotentiator. NOV-002 is also in Phase 2 development for
 chemotherapy-resistant ovarian cancer and early-stage breast cancer.
 NOV-205 acts as a hepatoprotective agent with immunomodulating and
 anti-inflammatory properties. NOV-205 is in Phase 1b development for
 chronic hepatitis C non-responders. Both compounds have completed
 clinical trials in humans and have been approved for use in the
 Russian Federation where they were originally developed.
Company: NPS Pharmaceuticals
Ticker Symbol & Exchange: NPSP - NASDAQ
Investor Relations Contact: Susan Mesco
Investor Relations Contact
 Phone: 908-450-5516
Web: www.npsp.com
Date of Presentation: 11/11/2008
NPS Pharmaceuticals is a New Jersey based biopharmaeutical company
 focused on the development and commercialization of specialty
 therpaeutics for gastrointestinal and endocrine disorders with high
 unmet medical needs. The company is currently advancing two late-
 stage programs. Teduglutide, a proprietary analog of GLP-2, is in
 Phase 3 clinical development for intestinal failure associated with
 short bowel syndrome as GATTEX and in preclinical development for
 gastrointestinal mucositis and pediatric gastrointestinal
 conditions. NPSP558 (parathyroid hormone 1-84 (rDNA origin)
 injection) is in Phase 2 clinical development as hormone therapy for
 hypoparathyroidism. NPS complements its proprietary programs with a
 royalty-based portfolio of products and product candidates that
 includes partnerships with Amgen, GSK, Kirin and Nycomed.
Company: Nuinsco Resources Limited.
Ticker Symbol & Exchange: Toronto, symbol NWI
Investor Relations Contact: Sean Stokes
Investor Relations Contact
 Phone: 416-626-0470
Web: www.nuinsco.ca
Date of Presentation: Nov. 12
Nuinsco is a growth-oriented, multi-commodity mineral exploration and
 development company that is prepared for production and focused on
 growth through nickel, copper, zinc, uranium and gold exploration
 and development in world-class mineralized belts in Canada and
 Turkey. Shares of Nuinsco trade on the Toronto Stock Exchange under
 the symbol NWI.
Company: OMNI Energy Services Corp
Ticker Symbol & Exchange: OMNI NASDAQ
Investor Relations Contact: Ron Mogel, Sr. Vice President &
 Chief Financial Officer
Investor Relations Contact
 Phone: 337/896-6664
Web: omnienergy.com
Date of Presentation: November 11, 2008, 10:20 a.m. -
 Spellman Salon (5th Floor)
Formed in 1987, OMNI Energy Services Corp. has evolved into a premier
 service provider to the oil and gas industry. Through our integrated
 services group of companies we focus on three core business units:
 Seismic Services, Land Operations, and Offshore Operations. Our
 activities are concentrated in the most prolific regions in the
 U.S.; on land, inland and offshore. OMNI Seismic Drilling is the
 unmatched provider of choice among companies engaged in acquisition
 of 3D seismic data in regions we serve. From exploration through
 drilling and production, OMNI has the scale and scope to be our
 customers' single-source provider of choice.
Company: Oncolytics Biotech Inc.
Ticker Symbol & Exchange: TSX:ONC, NASDAQ:ONCY
Investor Relations Contact: Cathy Ward
Investor Relations Contact 403.670.7370,
 Phone: [email protected]
Web: www.oncolyticsbiotech.com
Date of Presentation: Nov. 11
Oncolytics Biotech Inc. is conducting a broad clinical trial program
 in the U.S. and the U.K. with the objective of developing
 REOLYSIN(R) as a human cancer therapeutic. The current clinical
 program includes 12 Phase I/II or Phase II human trials examining
 REOLYSIN(R) alone or in combination with radiation, chemotherapy, or
 immune modulation.
This broad clinical program is designed to identify targets for late-
 stage registration trials with REOLYSIN(R). The current program is
 treating patients with a wide variety of advanced cancers including
 head & neck, sarcoma, non-small cell lung, melanoma and ovarian.
Company: OncoVista Innovative Therapies, Inc.
Ticker Symbol & Exchange: OVIT.OB
Investor Relations Contact: Aimee Boutcher
Investor Relations Contact
 Phone: (973) 239-2878
Web: http://www.oncovista.com
Date of Presentation: 11/11/2008
We are a biopharmaceutical company that is commercializing diagnostic
 tests for metastatic tumors as well as developing targeted
 anticancer therapies by utilizing tumor-associated biomarkers. Our
 metastatic breast and colon cancer kits are marketed in Europe and a
 CLIA lab is established in US. Biomarker use should increase
 clinical response rates, thereby expediting drug development and
 reducing costs. Our targeted drugs are:
--OVI 123 - Phase I/II leukemia trial underway in US at two sites
--OVI 237 - Phase II metastatic breast cancer trial planned for
 Europe
--OVI-117 - IND in preparation for solid tumor clinical trial
Company: Oramed Pharmaceuticals
Ticker Symbol & Exchange: OTC BB:ORMP
Investor Relations Contact: Eric Rosenberg
Investor Relations Contact
 Phone: 972 545 667713
Web: www.oramed.com
Date of Presentation: Nov 11: from 04:05 to 04:30 PM
Oramed Pharmaceuticals is a technology pioneer in the field of oral
 delivery solutions for drugs and vaccines presently delivered via
 injection. Oramed is seeking to revolutionize the treatment of
 diabetes through its patented flagship product, an orally ingestible
 insulin capsule currently in phase 2 clinical trials. Established in
 2006, Oramed's technology is based on over 25 years of research by
 top research scientists at Jerusalem's Hadassah Medical Center. The
 Company's corporate and R&D headquarters are based in Jerusalem.
Company: Osteologix, Inc.
Ticker Symbol & Exchange: OTCBB: OLGX
Investor Relations Contact: Baxter Phillips, III
Investor Relations Contact
 Phone: 804-747-6026
Web: www.osteologix.com
Date of Presentation: Monday, November 10, 2008
Osteologix is a specialty pharmaceutical company committed to
 developing innovative therapies for the treatment and prevention of
 musculoskeletal diseases. It is our vision to improve the health of
 those afflicted with musculoskeletal diseases such as osteoporosis.
 We partner with the healthcare community to apply new scientific
 information and clinical data to the development of products that
 improve patient care in a safe and ethical manner. Osteologix's lead
 product candidate, NB S101, is a novel pharmaceutical agent for the
 treatment and prevention of osteoporosis.
Company: Oxygen Biotherapeutics, Inc.
Ticker Symbol & Exchange: OXBO:OTCBB
Investor Relations Contact: Abe Wischnia
Investor Relations Contact
 Phone: 619-795-2345
Web: www.oxybiomed.com
Date of Presentation: Nov. 12, 2008
Oxygen Biotherapeutics, Inc. is dedicated to commercializing
 innovative pharmaceuticals and medical devices in the field of
 oxygen therapeutics and continuous substrate monitoring. The Company
 has under development a perfluorocarbon therapeutic oxygen carrier
 and liquid ventilation product (Oxycyte(R)) and an implantable
 glucose sensor. These products are based upon core technologies that
 include biomedical applications for PFCs and medical and industrial
 applications for biosensors. Each of the product candidates is
 designed with advantages over currently marketed products in major
 markets including traumatic brain injury, sickle cell crisis pain,
 trauma, wound care, acute respiratory distress syndrome, stroke,
 myocardial infarction, surgery, and diabetes.
Company: PAION AG
Ticker Symbol & Exchange: PA8 (FSE), PAI (AIM)
Investor Relations Contact: Dr. Peer Nils Schroeder
Investor Relations Contact
 Phone: 49 241 4453-152
Web: www.paion.com
Date of Presentation: 11/10/2008
PAION is a biopharmaceutical company headquartered in Aachen,
 Germany. Since the acquisition of CeNeS Pharmaceuticals in June
 2008, the company has a second site in Cambridge, UK. The company is
 specializing in developing and commercializing innovative drugs for
 the hospital-based treatment of CNS disorders and
 thrombotic/cardiovascular diseases, indications for which there is a
 substantial unmet medical need. PAION intends to further expand its
 portfolio of drugs by exploiting its core expertise in identifying
 high-potential compounds, licensing or otherwise acquiring them and
 advancing them through the clinical development and regulatory
 approval process. Where appropriate, PAION seeks to collaborate with
 experienced partners.
Company: PanTerra Resource Corp
Ticker Symbol & Exchange: 'PAN' - TSX-V
Investor Relations Contact: Fred Rumak
Investor Relations Contact Herve Collet, 403-261-5900
 Phone:
Web: www.panterraresource.com
Date of Presentation: 11/12/2008
PanTerra Company Overview:
-3 years from idea to reality
-Large land base, 1.1 million acres (550,000 net) acquired in 2005
 and earned in 2006.
-Drilled and cased 39 wells to date.
-Extensive coring and geochemical sampling.
-Developing resource play to "proven reserve" stage.
-Widely held stock base with one major shareholder at 15%
-Proving reserve base with leading edge technology out of the USA.
-Management has over 67 years experience in engineering and geology
 with both domestic and international experience and 40 plus years of
 financial experience.
-Objective is to prove reserve base and develop same and or dispose
 of same to larger entity.
-Strategically located geographic location of land.
Company: Parallel Petroleum Corporation
Ticker Symbol & Exchange: NASDAQ: PLLL
Investor Relations Contact: Cindy Thomason, Mgr Inv Rel
Investor Relations Contact
 Phone: 432-684-3727
Web: www.plll.com
Date of Presentation: Tuesday, November 11, 2008
Parallel Petroleum is an independent energy company headquartered in
 Midland, Texas, engaged in the exploitation, development,
 acquisition, and production of oil and gas using 3-D seismic
 technology and advanced drilling, completion and recovery
 techniques, including horizontal drilling and fracture stimulation.
 Parallel's primary areas of operation are the Permian Basin of West
 Texas and New Mexico, North Texas Barnett Shale, Onshore Gulf Coast
 of South Texas, East Texas and Utah/Colorado.
Company: Pelangio Exploration Inc.
Ticker Symbol & Exchange: PX
Investor Relations Contact: Brendan Cahill
Investor Relations Contact
 Phone: 905-875-3828
Web: www.pelanigo.com
Date of Presentation: November 11, 2008 at 4:05 - 4:30 PM
Pelangio is a Canadian junior mineral exploration company, with a
 focus on gold, active in two of the top-ranked mining jurisdictions
 in the world, Canada and Ghana. The Company focuses on the
 acquisition and exploration of under-valued or early stage
 exploration prospects located in world-class gold belts, where
 discovery can provide a significant return on investment.
Company: Peplin
Ticker Symbol & Exchange: ASX: PLI
Investor Relations Contact: Tom Wiggans
Investor Relations Contact
 Phone: 510-653-9702
Web: www.peplin.com
Date of Presentation: November 11, 2008
Peplin is a development stage pharmaceutical company focused on
 advancing and commercializing innovative medical dermatology
 products. We are currently developing our patented PEP005 (ingenol
 mebutate), first in a new class of compounds that is extracted and
 purified from Euphorbia peplus, a readily-available plant.
Our lead product candidate, currently in PIII trials (REGION-I) under
 an SPA, is a patient-applied gel containing PEP005 for the treatment
 of actinic keratosis (AK). AK is generally considered the most
 common pre-cancerous skin condition, where lesions may progress to
 squamous cell carcinoma.
After completing a $24m financing, Peplin has $56m, sufficient to
 complete Phase III development.
Company: PhotoMedex, Inc.
Ticker Symbol & Exchange: NasdaqGM: PHMD
Investor Relations Contact: Kim Golodetz
Investor Relations Contact
 Phone: (212) 838-3777
Web: [email protected]
Date of Presentation: 11/11/2008
PhotoMedex offers a wide range of products and services across
 multiple specialty areas, including dermatology, urology,
 gynecology, orthopedics and other surgical specialties. PhotoMedex
 is a leader in the development, manufacturing and marketing of
 medical laser products and services. PhotoMedex also develops and
 markets products based on its patented, clinically proven Copper
 Peptide technology for skin health, hair care and wound care.
 PhotoMedex sells directly to dermatologists, plastic and cosmetic
 surgeons, spas and salons and through licenses with strategic
 partners into the consumer market, including a long-term worldwide
 license agreement with Neutrogena(R), a Johnson & Johnson company.
 ProCyte brands include Neova(R), Ti-Silc(R), VitalCopper(R), Simple
 Solutions(R) and AquaSante(R).
Company: Polaris Minerals Corporation
Ticker Symbol & Exchange: PLS:TSX
Investor Relations Contact: Mike Westerlund
Investor Relations Contact 604.915.5000 ext 104
 Phone:
Web: www.polarmin.com
Date of Presentation: 11/11/2008
Polaris Minerals Corporation is exclusively focused on the
 development of quarries and the production of construction
 aggregates on Vancouver Island, British Columbia, for marine
 transport by bulk carriers to urban markets on the west coast of
 North America to meet growing local supply deficits.
In 2007, Polaris began shipping sand and gravel from the Orca Quarry
 to readymix concrete companies in San Francisco, Vancouver and
 Hawaii. Polaris has long-term supply contracts with its customers
 and stable, long-term shipping contracts.
Polaris owns 88 percent of the Orca Quarry and 70 percent of the
 proposed Eagle Rock Quarry.
Company: Prana Biotechnology Ltd
Ticker Symbol & Exchange: NASDAQ:PRAN/ASX:PBT
Investor Relations Contact: Leslie Wolf-Creutzfeldt
Investor Relations Contact
 Phone: 646-284-9472
Web: www.pranabio.com
Date of Presentation: Nov 10, 9:55am
Prana Biotechnology Limited ("Prana") was established to
 commercialize research into Alzheimer's disease and other major age-
 related degenerative disorders. Its mission is to develop diagnostic
 and therapeutic drugs to treat the central disease pathways that
 cause degeneration for the brain as the aging process progresses.
Researchers at prominent international institutions including the
 University of Melbourne, the Mental Health Research Institute
 (Melbourne), and Massachusetts General Hospital, a teaching hospital
 of Harvard Medical School, discovered Prana's technology. Prana is
 now regarded as one of the leading contenders in the field of neuro-
 degenerative disease. Prana has completed Phase IIa trial with its
 leading compound PBT2 and has obtained positive results.
Company: Provectus Pharmaceuticals, Inc.
Ticker Symbol & Exchange: PVCT:BB
Investor Relations Contact: Peter R. Culpepper
Investor Relations Contact
 Phone: 866-594-5999 #30
Web: www.pvct.com
Date of Presentation: November 11th, 2008
Provectus Pharmaceuticals is a development stage company that
 specializes in oncology and dermatology therapies that are safer,
 more effective, less invasive and more economical than conventional
 therapies. Provectus is currently conducting Phase 2 clinical trials
 of their proprietary drugs PV-10 as a therapy for metastatic
 melanoma and PH-10 as a topical treatment for psoriasis and atopic
 dermatitis. The Company has received orphan drug designation from
 the FDA for its melanoma indication. Complementing their suite of
 proprietary drugs, Provectus has developed a number of intellectual
 properties and technologies in the areas of imaging, medical devices
 and biotechnology.
Company: Puda Coal, Inc.
Ticker Symbol & Exchange: PUDC
Investor Relations Contact: Ms Laby Wu
Investor Relations Contact
 Phone: 86-139-1129-6720
Web: www.pudacoalinc.com
Date of Presentation: 11:35 am - 12:00 pm on Nov. 11th 08
Puda Coal, through its subsidiaries, supplies premium grade coking
 coal to the steel making industry in China for use in making coke.
 The company currently possesses 3.5 million metric tons of annual
 coking coal cleaning capacity. Shanxi Province provides 20 - 25% of
 China's coal output and supplies nearly 50% of China's coke. For
 more information, visit www.pudacoalinc.com.
Company: QRxPharma
Ticker Symbol & Exchange: ASX:QRX -OTCQX:QRXP
Investor Relations Contact: John Holaday
Investor Relations Contact [email protected], 908-506-
 Phone: 2900
Web: www.qrxpharma.com
Date of Presentation: November 10, 2008, 12:25 pm, Holmes
QRxPharma is a clinical-stage specialty pharmaceutical company
 focused on the development and commercialization of new treatments
 for pain management and central nervous system (CNS) disorders.
 Based on a business strategy to expand the clinical utility and
 commercial value of marketed and/or existing compounds, the
 Company's product portfolio includes both late and early stage
 clinical drug candidates with well-defined paths to regulatory
 approval and sales. The worldwide market for the treatment of
 moderate to severe pain with opioids exceeds $10BB, and in the US,
 $7BB annually. QRxPharma intends to directly commercialize its
 products in the US and seek strategic partnerships abroad.
Company: Raptor Pharmaceuticals Corp.
Ticker Symbol & Exchange: RPTP.OB
Investor Relations Contact: Sara Ephraim, The Ruth Group
Investor Relations Contact
 Phone: 646.536.7002
Web: www.raptorpharma.com
Date of Presentation: Nov. 11, 9:30-9:55 am, Holmes II
Raptor Pharmaceuticals Corp. (OTCBB: RPTP) is dedicated to speeding
 the delivery of new treatment options by working to improve existing
 therapeutics through the application of highly specialized drug
 targeting platforms and formulation expertise. Raptor is developing
 its proprietary Delayed-Release Cysteamine ("DR Cysteamine") product
 candidate in nephropathic cystinosis, non-alcoholic steatohepatitis
 ("NASH"), Huntington's Disease and Batten Disease, and its Convivia
 product candidate in aldehyde dehydrogenase ("ALDH2") deficiency. In
 its preclinical program Raptor bioengineers novel drug candidates
 and drug-targeting platforms derived from the human receptor-
 associated protein ("RAP") and related proteins which are designed
 to target cancer, neurodegenerative disorders and infectious
 diseases.
Company: Reed Resources Ltd
Ticker Symbol & Exchange: RDR:ASX
Investor Relations Contact: Simon Hicks
Investor Relations Contact
 Phone: 61-8-9322 1182
Web: www.reedresources.com
Date of Presentation: 11/11/2008
Reed Resources Ltd intends on being one of the world's lowest cost
 producers of ferrovanadium. It is currently carrying out a
 Definitive Feasibility Study into the production of 6300t p.a. of
 ferrovanadium from it's Barrambie Vanadium Project.
Reed Resources is also a gold miner and an active explorer for gold
 and base metals in Western Australia.
The company is listed on the Australian Securities Exchange (ASX
 Code: RDR).
Company: Repros Therapeutics Inc.
Ticker Symbol & Exchange: RPRX
Investor Relations Contact: Joe Podolski
Investor Relations Contact
 Phone: 281-719-3447
Web: www.reprosrx.com
Date of Presentation: 11/11/2008
Repros Therapeutics Inc. is a clinical-stage biopharmaceutical
 company focused on the development of new, orally administered,
 small molecule drugs to treat hormonal and reproductive system
 disorders. The company has two lead product candidates.
Proellex(R), for the treatment of adverse symptoms associated with
 uterine fibroids, has shown statistically significant improvement in
 the primary endpoints in Phase 2 trials. Also Proellex(R) has
 demonstrated superior efficacy and safety in endometriosis when
 compared to the standard of drug care and is currently in Phase 2.
Androxal(TM), for the treatment of testosterone deficiency, has shown
 highly statistically significant positive effects in men with
 secondary hypogonadism and is in Phase 2.
Company: Rex Energy Corporation
Ticker Symbol & Exchange: REXX
Investor Relations Contact: Joseph DeSimone
Investor Relations Contact
 Phone: 814-278-7129
Web: www.rexenergy.com
Date of Presentation: November 11, 2008 @ 4:30 p.m.
Rex Energy Corporation is an independent oil and gas company
 operating in the Illinois Basin, the Appalachian Basin and the
 Southwestern Region of the United States. The company has pursued a
 balanced growth strategy of exploiting its sizable inventory of
 lower risk developmental drilling locations, pursuing its higher
 potential exploration drilling prospects and actively seeking to
 acquire complementary oil and natural gas properties.
Company: Rib-X Pharmaceuticals, Inc.
Investor Relations Contact: John Capodanno
Investor Relations Contact
 Phone: 212-850-5705
Web: www.rib-x.com
Date of Presentation: 11/10/2008
Rib-X Pharmaceuticals, Inc. is designing and developing novel
 antibiotics. Rib-X's underlying drug discovery engine combines its
 proprietary high-resolution X-ray crystal structure of the 50S
 ribosome and computational tools to rapidly synthesize new
 antibiotics that avoid known resistance mechanisms and have a
 superior spectrum. Rib-X has four programs; radezolid an oral/IV
 oxazolidinone for treating serious Gram-positive infections and
 delafloxacin, a fluoroquinolone active against quinolone-resistant
 Gram-positive bacteria and MRSA, both having completed Phase 2
 clinical studies; and two pre-clinical programs, Rx-04 a novel class
 of antibiotics active against multi-drug resistant Gram-negative
 bacteria and Rx-02 an IV/oral macrolide for MRSA and multidrug-
 resistant Streptococcus.
Company: Richmont Mines, Inc.
Ticker Symbol & Exchange: TSX-NYSEAlternext
Investor Relations Contact: James M. Culligan
Investor Relations Contact
 Phone: 716-843-3874
Web: www.richmont-mines.com
Date of Presentation: 11/10/2008
Richmont Mines produces gold from its operations in Canada and is
 focused on building its reserves in North America. The Company has
 extensive experience in gold exploration, development and mining.
 Since it began production in 1991, the Company has produced more
 than one million ounces of gold from its holdings in Quebec, Ontario
 and Newfoundland.and Labrador. Richmont Mines' strategy is to cost
 effectively develop its mining assets, exploit mineralized reserves
 on properties owned and acquired, or develop partnerships to expand
 its reserve base.
Company: RINO International Corp.
Ticker Symbol & Exchange: RINO OTCBB
Investor Relations Contact: HC International, Inc.
Investor Relations Contact Ted Haberfield, 760-755-2716
 Phone:
Web: www.rinogroup.com
Date of Presentation: 11/12/2008
Rino develops, produces and installs pollution control and Cleantech
 equipment for customers operating in China's Iron and Steel sector.
 RINO has three specific areas its products address which include
 water, air and production efficiency. As the government continues to
 implement more stringent emission and pollution standards, the
 Company's products have seen a significant increase in demand, as
 its customized desulphurization equipment have been a primary driver
 during the previous 12 months.
Company: Rockwell Medical Technologies, Inc.
Ticker Symbol & Exchange: NASDAQ: RMTI
Investor Relations Contact: Brian Korb
Investor Relations Contact
 Phone: 646-378-2923
Web: http://www.rockwellmed.com/
Date of Presentation: 11/12/2008
Rockwell Medical is a leading, innovative manufacturer and developer
 of renal drug therapies and dialysis products. Rockwell's products
 are used to maintain life, removing toxins and replacing nutrients
 in the dialysis patient's bloodstream. SFP, the Company's lead renal
 drug, is a water-soluble iron designed to provide physiological-
 iron-maintenance-therapy for the treatment of anemia, with initial
 indication for end stage renal disease (ESRD). There are an
 estimated 370,000 ESRD patients in the United States growing
 approximately 3-5% on average each year and approximately 2 million
 ESRD patients world-wide. SFP is currently in Phase II-b and NIH-
 funded studies, with data expected next year.
Company: Santaris Pharma A/S
Investor Relations Contact: Randi Krogsgaard
Investor Relations Contact
 Phone: 45 45179879
Web: www.santaris.com
Date of Presentation: 11.11.08
Santaris Pharma is a Danish clinical stage biopharmaceutical company
 formed in 2003. The Company has exclusive pharmaceutical rights to
 LNA technology used to develop new classes of RNA medicines to
 silence mRNAs and microRNAs associated with cancer, metabolic
 disorders and viral infections. In 2006 the Company completed a Euro
 40m second round and in 2007 a Euro 20m third round of equity
 financing. Santaris Pharma has a global alliance with Enzon
 Pharmaceuticals to develop and co-commercialise cancer drugs and a
 worldwide strategic alliance with GlaxoSmithKline for the discovery,
 development and commercialization of antiviral medicines. In May
 2008 the Company initiated the world's first human trial with a
 microRNA drug candidate, SPC3649, targeting microRNA-122, which is
 associated with HCVreplication in the liver.
Company: SciClone Pharmaceuticals
Ticker Symbol & Exchange: NASDAQ: SCLN
Investor Relations Contact: Ana Kapor
Investor Relations Contact
 Phone: 650 350 4825
Web: www.sciclone.com
Date of Presentation: Wednesday, November 12 2008
SciClone Pharmaceuticals, Inc. is a biopharmaceutical company engaged
 in the development and commercialization of novel therapeutics to
 treat life-threatening diseases. SciClone's strategy is to develop
 late-stage clinical products for commercialization in the United
 States, Europe, and China, one of the world's fastest growing
 pharmaceutical markets.
Company: Shiner International, Inc.
Ticker Symbol & Exchange: BEST (NASDAQ)
Investor Relations Contact: Mr. Arnold Staloff
Investor Relations Contact
 Phone: 212-631-3510
Web: www.shinerinc.com
Date of Presentation: 11/12/2008 15:15
Shiner International, Inc. is a highly profitable U.S. public company
 with its main business in China.
Shiner is China's leading manufacturer and marketer of four types of
 technology driven packaging film products: anti-counterfeit films,
 coated films, BOPP films and color printed films. Serving customers
 worldwide, Shiner is one of the few large scale global suppliers
 dedicated to the manufacturing of advanced packaging films. Our
 products are used to seal in freshness and flavor, protect goods
 from product tampering, and extend foods and beverages shelf life.
 Shiner holds 13 patents on products and production equipment with
 additional patents pending.
Company: Silver Shield Resources Corp.
Ticker Symbol & Exchange: SSR: TSX.V
Investor Relations Contact: Lindsay Carpenter
Investor Relations Contact [email protected], 416-868-1079 ext.
 Phone: 239
Web: www.silvershieldresources.com
Date of Presentation: 11/10/2008
Silver Shield Resources is a mineral exploration company established
 to discover and develop mineral resources, with a focus on silver
 and an interest in gold. Silver Shield's corporate objective is to
 acquire quality silver projects which are in advanced stages, beyond
 grassroots exploration and have the potential to be developed into
 producing properties. The company's properties are located in
 historical producing belts in Mexico and Northern Ontario, and are
 shallow deposits resulting in low cost exploration and development.
 The company's two flagship properties are 100% owned, with high
 grade assay results at mineable widths from a first phase of
 drilling on both these properties, La Cumbre (Mexico) and Welsh
 Silver Mine (Northern Ontario).
Company: Skygold Ventures Ltd.
Ticker Symbol & Exchange: TSX-V : SKV
Investor Relations Contact: Brad Aelicks
Investor Relations Contact
 Phone: 604.685.6465
Web: www.skygold.ca
Date of Presentation: 11/12/2008
Skygold Ventures is a Canadian junior mining company delineating a
 large bulk tonnage gold deposit at Spanish Mountain in central
 British Columbia, Canada. Skygold is in the process of updating its
 Spanish Mtn. NI 43-101 gold resource estimate of 1.75 million ounces
 measured and indicated and 100,000 ounces inferred. The company also
 has three additional early stage sediment hosted gold (SHG)
 properties located on the same developing gold belt as Spanish Mtn.
 This area hosts numerous gold placer operations but until now has
 never been recognized for its hard rock potential. Skygold has
 commenced geological mapping, trenching and initial drill programs
 on the additional properties.
Company: Smartheat, Inc.
Ticker Symbol & Exchange: SMHT (OTC BB)
Investor Relations Contact: Ms. Huajun Ai
Investor Relations Contact
 Phone: 86 24-25197699
Web: www.smartheatinc.com
Date of Presentation: 11/10/2008 9:55AM
SmartHeat is the leading publicly traded U.S. company operating in
 the highly profitable plate heat exchanger market in China. Our
 "green" plate heat exchanger (PHE) technology helps reduce fossil
 fuel related costs and pollution by capturing and recycling waste
 heat. Overall, industries using our products and technology consume
 less coal thereby lowering their CO2 emissions. As the developer of
 5 key patents across our product lines, we are poised to continue
 the expansion of our operations in China's heat transfer industry, a
 market currently estimated at approximately $2.4 billion dollars
 with double digit annual growth.
Company: Solar Power, Inc.
Ticker Symbol & Exchange: SOPW OTCBB
Investor Relations Contact: HC International, Inc.
Investor Relations Contact Ted Haberfield, 760-755-2716
 Phone:
Web: www.solarpowerinc.net
Date of Presentation: 11/12/2008
Founded in 2005, Solar Power, Inc. is a vertically integrated solar
 energy solution provider offering the North American commercial and
 public sector building markets a complete solution through a single
 brand. The company's Yes! Solar Solutions(TM) subsidiary provides
 the U.S. small- to mid-sized business and residential market
 segments with turnkey PV solar systems through a growing retail
 franchise network. Throughout Europe and Asia, the company sells its
 products direct to distributors and turnkey solutions providers.
 Solar Power, Inc. operates from its Roseville, California
 headquarters.
Company: SOYO Group Inc.
Ticker Symbol & Exchange: OTCBB: SOYO
Investor Relations Contact: Craig H. Bird
Investor Relations Contact [email protected], (215) 392-4981
 Phone:
Web: http://www.soyo.com/
Date of Presentation: Tuesday, November 11th
SOYO Inc. is an innovative provider of consumer electronics and IT
 products such as LCD Monitors, LCD HD Televisions, Bluetooth
 Devices, Portable Storage, and Home Theater Furniture products and
 services. Headquartered in Ontario, California, with additional
 sales offices in Latin America, SOYO sells its products through an
 extensive network of authorized retailers, distributors, resellers,
 system integrators, VARs, and ecommerce web sites. Products are sold
 under the SOYO, Dragon, Onyx, Dymond, Honeywell, Le Vello, and Prive
 brand names. For more information, please visit http://www.soyo.com.
 For information on the Honeywell Consumer Electronics product lines,
 please visit www.honeywellce.com.
Company: Stem Cell Therapeutics Corp.
Ticker Symbol & Exchange: SSS TSX Venture
Investor Relations Contact: Chloe Crampton
Investor Relations Contact
 Phone: (403) 245-5495
Web: www.stemcellthera.com
Date of Presentation: 11/12/2008
Stem Cell Therapeutics Corp. is a Canadian public biotechnology
 company (TSX-V: SSS) focused on the development and
 commercialization of drug-based therapies to treat central nervous
 system diseases. SCT is a leader in the development of therapies
 that utilize drugs to stimulate a patient's own resident stem cells.
 SCT's programs aim to repair neurological function lost due to
 disease or injury. SCT's lead clinical program REGENESIS, currently
 in Phase IIb, targets the treatment of stroke by repurposing
 approved and clinically well defined drugs. SCT's extensive patent
 portfolio of owned and licensed intellectual property supports the
 potential expansion into future clinical programs in numerous
 neurological diseases such as traumatic brain injury, multiple
 sclerosis, Huntington's disease, Alzheimer's disease, ALS.
Company: SUNESIS PHARMACEUTICALS, INC.
Ticker Symbol & Exchange: SNSS
Investor Relations Contact: Monique Greer
Investor Relations Contact
 Phone: (415) 946-1075
Web: www.sunesis.com
Date of Presentation: November 12, 2008 @ 2:00 p.m.
Sunesis is a clinical-stage biopharmaceutical company focused on the
 development and commercialization of new oncology therapeutics for
 the treatment of solid and hematologic cancers. Sunesis has built a
 highly experienced cancer drug development organization committed to
 advancing its lead product candidate, voreloxin, in multiple
 indications to improve the lives of people with cancer. Voreloxin is
 currently being evaluated in both frontline and relapsed/refractory
 acute myeloid leukemia and in platinum-resistant ovarian cancer. In
 clinical trials conducted to date, voreloxin has been generally well
 tolerated and has shown objective responses in both solid and
 hematologic tumor types.
Company: Syntaxin Ltd
Investor Relations Contact: Tim Pearce
Investor Relations Contact
 Phone: +44 1235 552112
Web: www.syntaxin.com
Date of Presentation: November 12th
Syntaxin is a biopharmaceutical company that designs and develops
 novel drugs for the treatment of chronic diseases that act by
 controlling cell secretion.
Cell secretion plays an important role in the development of numerous
 diseases, including respiratory, endocrine, inflammatory and
 metabolic disorders, certain cancers, as well as chronic pain.
Syntaxin's proprietary technology enables the generation of novel
 therapeutic proteins with broad applicability across these major
 disease areas.
Syntaxin's strategy is to develop these novel biologic drugs that
 control cell secretion, a completely new approach to addressing
 major markets, and to focus on respiratory, endocrine and
 inflammatory disorders within its own pre-clinical development
 pipeline.
Company: Targeted Genetics Corporation
Ticker Symbol & Exchange: TGEN:Nasdaq Capital Market
Investor Relations Contact: Stacie D. Byars; WeisComm Partners
Investor Relations Contact
 Phone: 415-946-1072
Web: www.targen.com
Date of Presentation: November 11th, 2008
Targeted Genetics Corporation develops and commercializes innovative,
 targeted, molecular therapies based on its proprietary DNA delivery
 platform, Adeno-Associated Virus (AAV), which can deliver DNA
 capable of encoding interfering RNA molecules such as miRNA or
 shRNA, or therapeutic proteins.
First to bring AAV vectors into the clinic, TGC has the deepest
 experience in the development, large-scale manufacture, and clinical
 trial experience using AAV. This experience has allowed the company
 to build numerous partnerships and alliances resulting in a diverse
 pipeline of clinical candidates for inflammatory arthritis, HIV
 vaccines, congenital blindness (LCA), congestive heart failure and
 preclinical candidates for Huntington's disease.
Company: TechPrecision Corporation
Ticker Symbol & Exchange: TPCS.OB, OTCBB
Investor Relations Contact: Mr. Crocker Coulson
Investor Relations Contact
 Phone: 646 213 1915
Web: www.techprecision.com
Date of Presentation: Wednesday, November 12, 2008
TechPrecision Corporation, through its wholly-owned subsidiary Ranor,
 Inc., manufactures large scale metal fabricated and precision
 machined components and equipment used in a variety of markets
 including: alternative energy, medical, nuclear, defense, industrial
 and aerospace. The Company is one of a few end-to-end solutions
 providers with the ability to engineer the requisite tooling and the
 entire manufacturing process for each respective production program,
 fabricate, machine, assemble, test and deliver large scale projects
 with tight tolerance levels. TechPrecision is one of the few
 manufacturers in the U.S. with American Society of Mechanical
 Engineers (ASME) Certifications and Authorizations, which allow the
 design and construction of commercial nuclear equipment, and nuclear
 storage and shipping equipment.
Company: ThromboVision, Inc.
Investor Relations Contact: Sally I Evans, APR
Investor Relations Contact office: 713-660-7990; mobile: 713-
 Phone: 557-2461
Web: www.thrombovision.com
Date of Presentation: 11/10/2008
ThromboVision, Inc. is a biomedical company committed to enabling
 people to lead longer and healthier lives. ThromboVision seeks to
 provide easy-to-use, rapid-response, cost-effective, and versatile
 point-of-care clinical diagnostic discoveries that advance medical
 diagnosis. The company's products -- under development and not yet
 released to market -- will improve medical care by assisting
 physicians in diagnosing and managing critical cardiovascular risk
 factors, especially those related to platelet function and
 antiplatelet drug therapy. The company has filed a 510(k)
 application with the FDA for its initial product, the
 ThromboGuide(R) (T-Guide(R)) platelet aggregation system.
 www.thrombovision.com
Company: Tianyin Pharmaceutical Co., Inc.
Ticker Symbol & Exchange: AMEX: TPI
Investor Relations Contact: HC International, Inc.
Investor Relations Contact Feng Peng, 917-558-7610
 Phone:
Web: www.tianyinpharma.com
Date of Presentation: 11/11/2008
Based in Chengdu, China, Tianyin Pharmaceutical Co., Inc. is a
 primary manufacturer, marketer and supplier of modernized
 Traditional Chinese Medicine (TCM). Established in 1994, the Company
 develops and manufactures a diversified portfolio consisting of 32
 branded, cost-competitive modernized TCMs and 4 generic western
 medicines addressing a number of indications through its two GMP-
 certified manufacturing facilities and sells its products through an
 extensive nationwide distribution network managed by over 720
 salespeople. Tianyin possesses a strong R&D platform supported by
 partnerships with leading Chinese academic institutions and has
 produced an extensive pipeline of 48 products in various stages of
 the approval process.
Company: Titan Pharmaceuticals, Inc.
Ticker Symbol & Exchange: TTP
Investor Relations Contact: Robert E. Farrell
Investor Relations Contact
 Phone: (650) 244-4990
Web: www.titanpharm.com
Date of Presentation: 11/10/2008
Titan Pharmaceuticals, Inc. (AMEX: TTP) is focused primarily on the
 late-stage development and commercialization of innovative
 treatments for central nervous system disorders. Probuphine, which
 utilizes Titan's proprietary ProNeura long term drug delivery
 technology, has demonstrated positive results in Phase III testing
 for the treatment of opiate addiction. The Company is also planning
 to develop this validated sustained drug delivery technology for
 other potential treatment applications in which conventional
 treatment is limited by variability in blood drug levels and poor
 patient compliance. Products based on ProNeura technology can
 provide controlled drug release on an outpatient basis over extended
 periods of up to 6-12 months. Titan also has two other products,
 gallium maltolate and DITPA, in earlier stages of development.
Company: TMNG Global
Ticker Symbol & Exchange: TMNG: NASDAQ
Investor Relations Contact: Corey Kinger
Investor Relations Contact
 Phone: 212.986.6667
Web: www.tmng.com
Date of Presentation: 11/11/2008
TMNG Global provides strategy and management consulting, software
 solutions, and other products and services, to more than 1,200
 converging communications, entertainment, media and technology
 companies and financial services firms worldwide. The company is
 headquartered in Overland Park, Kansas, with offices in Boston,
 Chicago, London, New York, Shanghai and Washington, D.C.
TMNG tackles complex business problems and propels clients to
 profitable growth, optimal performance and sustainable competitive
 advantage.
TMNG Global assists clients in addressing transformational issues.
 TMNG Global is singularly focused on helping clients improve their
 bottom line performance, whether by designing new strategies,
 optimizing organizations and processes, or implementing new systems,
 operations, products and services.
Company: Tongxin International, Ltd.
Ticker Symbol & Exchange: NASDAQ: TXIC
Investor Relations Contact: HC International, Inc.
Investor Relations Contact
 Phone: 914-669-5340
Web: www.hntx.com
Date of Presentation: 11/11/2008
Tongxin International Ltd. is a company focusing on China's fast-
 growing commercial vehicle market throught its initial combination
 of its wholly owned subsidiary, Hunan Tongxin Enterprise Ltd. It is
 the largest independent OEM supplier of Engineered Vehicle Body
 Structures ("EVBS") in China. The Company is capable of providing
 EVBS for both the commercial vehicle and light vehicle market
 segments, in addition to designing, fabricating and testing dies
 used in the manufacturing process. Tongxin services more than 130
 commercial vehicle manufactures in China and select export markets.
 Tongxin International has agreements in place to acquire Meihua Bus,
 a passenger bus manufacturer and a strategy to arcquire related
 automotive parts manufacturers in the near term.
Company: Ukrzernoprom Agro LLC
Ticker Symbol & Exchange: Frankfurt: 4GW1 GR
Investor Relations Contact: Inna Dekhtiar
Investor Relations Contact
 Phone: 380 44 499 32 40
Web: www.uzp-agro.com.ua
Date of Presentation: November 11, 9:30-10:55
Ukrzernoprom Agro is one of the leading crop raising companies in
 Ukraine. Growing and selling crops, wheat, rapeseed, barley,
 sunflower seed and corn is the Company's main line of business. It
 operates on more than 100 thousand hectare of fertile land.
Ukrzernoprom Agro tripled the previous year's production and
 harvested more than 240 thousand tons of grain-crops in 2008. Its
 yields are usually 25-35 % higher than average yields in Ukraine
 owing to use of new technologies, state-of-the-art land cultivation
 methods and energy saving technilogies. Ukrzernoprom Agro is the
 only Ukrainian crop growing company certified according to ISO
 9001:2000 standards.
Company: Uranerz Energy Corporation
Ticker Symbol & Exchange: AMEX and TSX: URZ
Investor Relations Contact: Dennis Higgs
Investor Relations Contact
 Phone: 604-689-1659
Web: www.uranerz.com
Date of Presentation: 11/10/2008
Uranerz Energy Corporation is a pure-play uranium company focused on
 production. Members of the Uranerz management team have specialized
 expertise in the in-situ recovery ("ISR") uranium mining method.
 Uranerz controls approximately 122,500 acres in the Pumpkin Buttes
 Uranium Mining District of the central Powder River Basin ("PRB") of
 Wyoming, U.S.A., an area well-known for hosting uranium-mineralized
 roll fronts often amenable to ISR mining techniques.
Uranerz has submitted federal and state mining applications to build
 and operate its Nichols Ranch ISR Uranium Complex. Upon receipt of
 required regulatory approvals, Nichols Ranch will host the main
 processing facility and also service the Company's planned future
 satellite plants in the PRB.
External Validation: Denison Mines Corp. strategic investment - owns
 9.9% of Uranerz.
Company: Vaxin Inc.
Investor Relations Contact: Bill Enright
Investor Relations Contact [email protected], 205-909-3751
 Phone:
Web: www.vaxin.com
Date of Presentation: 11/12/2008
Vaxin is a clinical stage vaccine development company with
 innovative, single-dose, needle-free, cell-culture manufactured
 product candidates. Our lead indication is Influenza where we have
 shown proof of principle in people with a safe and well tolerated
 nasally administered seasonal vaccine that had a significant immune
 response in healthy volunteers. We are currently enrolling
 volunteers in a nasally administered Ph I pandemic vaccine (H5N1)
 study.
Vaxin's pipeline includes pre-clinical programs in anthrax, where we
 have shown 100% protection against lethal Ames spore challenge in
 two animal models and Alzheimer's disease vaccines. We also are
 developing several animal health vaccines, including an influenza
 vaccine delivered in ovo and an immunocontraceptive vaccine.
Company: Victory Nickel Inc.
Ticker Symbol & Exchange: Toronto, symbol NI
Investor Relations Contact: Sean Stokes
Investor Relations Contact
 Phone: 416-363-8527
Web: www.victorynickel.ca
Date of Presentation: Nov. 11
Victory Nickel Inc. is a Canadian company with three sulphide nickel
 deposits containing significant 43-101-compliant nickel resources.
 Victory Nickel is focused on becoming a mid-tier nickel producer by
 developing its existing properties, Minago and Mel in Manitoba, and
 Lac Rocher in northwestern Quebec, and by evaluating opportunities
 to expand its nickel asset base. Victory Nickel also owns
 approximately 84% of the outstanding shares of Independent Nickel
 Corp. ("Independent") (TSX:INI).
Company: VirtualScopics, Inc.
Ticker Symbol & Exchange: VSCP
Investor Relations Contact: Molly Henderson
Investor Relations Contact
 Phone: 585.249.6231
Web: www.virtualscopics.com
Date of Presentation: 11/12/2008
VirtualScopics, Inc. is a leading provider of imaging solutions to
 accelerate drug and medical device development. The Company has
 developed a robust software platform for analysis and modeling of
 both structural and functional medical images. In combination with
 its industry-leading experience and expertise in advanced imaging
 biomarker measurement, this platform provides a uniquely clear
 window into the biological activity of drugs and devices in clinical
 trial patients, allowing sponsors to make better decisions faster.
 The Company is currently working with 12 of the leading 15
 pharmaceutical, biotechnology and medical device companies in the
 world.
Company: Vitae Pharmaceuticals
Investor Relations Contact: Lilian Stern
Investor Relations Contact
 Phone: 212-362-1200
Web: www.vitaepharma.com
Date of Presentation: 11/11/2008
Vitae Pharmaceuticals is an emerging pharmaceutical company with a
 unique, powerful structure based drug design engine and a rapidly
 maturing portfolio of high value discovery programs. Vitae's lead
 program is in renin inhibition for cardiovascular disease, and is
 expected to enter the clinic in 2009. Vitae also has an 11-beta HSD1
 diabetes / metabolic syndrome program, partnered in 4Q 2007 with
 Boehringer-Ingelheim, and an early but rapidly progressing BACE
 program for Alzheimer's. Vitae's goal is to discover and develop
 innovative new medicines with best in class potential in important
 therapeutic areas such as cardiovascular and metabolic disease, CNS
 and inflammation.
Company: VIVALIS
Ticker Symbol & Exchange: VLS.PA
Investor Relations Contact: Steve Grobet / Emmanuel Huynh
Investor Relations Contact
 Phone: 33 (0) 1 44 71 94 91
Web: www.vivalis.com
Date of Presentation: 11/10/2008
Vivalis (NYSE-Euronext: VLS.PA) is a biopharmaceutical company that
 provides innovative cell-based solutions for the industrial
 production of viral vaccines and therapeutic proteins and develops
 drugs to prevent and treat viral diseases.
Vivalis offers research and commercial licenses for its EB66(R) cell
 line, to pharmaceutical and biotechnology companies for the
 production of viral vaccines and therapeutic proteins. Vivalis
 receive up front, milestones and royalties payments on its licensees
 net sales. VIVALIS has established numerous partnerships with world
 leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline,
 Schering Plough, Bavarian Nordic, Acambis, Kaketsuken, CSL, Merial
 and SAFC Biosciences,
Company: WaferGen Biosystems
Ticker Symbol & Exchange: OTCBB: WGBS
Investor Relations Contact: Rachel Lipsitz
Investor Relations Contact
 Phone: 858-4499575
Web: www.wafergen.com
Date of Presentation: 11/10/2008
WaferGen Biosystems, Inc. is a leader in the development, manufacture
 and sale of state-of-the-art systems for gene expression,
 genotyping, cell biology and stem cell research for the life science
 and pharmaceutical industries. The company is actively developing
 its SmartChip(TM) product for the gene expression and genotyping
 markets. SmartChip is being developed as the first whole genome,
 high throughput gene expression real-time polymerase chain reaction
 (PCR) platform. WaferGen currently markets its SmartSlide(TM) family
 of products to companies and organizations involved in stem cell and
 cell biology research.
Company: WorldWater & Solar Technologies
Ticker Symbol & Exchange: OTC BB: WWAT
Investor Relations Contact: Chris Witty
Investor Relations Contact
 Phone: 646-438-9385
Web: www.worldwater.com
Date of Presentation: 11/12/2008
WorldWater & Solar Technologies Corp. is a full-service solar
 electric engineering, design and water management company with
 unique, high-powered and patented solar technology solutions to a
 broad spectrum of electricity and water supply problems. Earlier in
 2008, WorldWater merged with ENTECH, Inc., a high-technology solar
 energy company specializing in patented solar concentrating and PVT
 (thermal) systems. ENTECH's systems can produce electrical output, a
 combination of electricity and thermal energy, or thermal energy
 alone. Commercial applications vary in size from one kilowatt remote
 power units to large, multi-megawatt utility power plants. For more
 information go to www.worldwater.com.
Company: ZBB Energy Corporation
Ticker Symbol & Exchange: ZBB
Investor Relations Contact: SMH Market & Liquidity Service
Investor Relations Contact Joanne Verkuilen, 212-893-1122
 Phone:
Web: www.zbbenergy.com
Date of Presentation: 11/10/2008
ZBB Energy Corporation (ZBB) provides clean energy storage solutions
 based on proprietary zinc rechargeable energy storage technology
 that addresses requirements in multiple markets such as alternative
 energy applications, large electrical utilities and green
 residential and commercial architecture. A developer and
 manufacturer of its modular, transportable and environmentally
 friendly Zinc Energy Storage Systems ("ZESS'), ZBB Energy was
 founded in 1998 and is headquartered in Wisconsin with offices
 located in Perth, Australia.
Company: Zelos Therapeutics, Inc.
Investor Relations Contact: Alan Roemer, CFO
Investor Relations Contact
 Phone: (610) 825-1468
Web: http://www.zelostherapeutics.com
Date of Presentation: 11/10/2008
Zelos Therapeutics is developing therapeutics for the treatment of
 osteoporosis and other bone diseases. Our lead clinical compound,
 ZT-031, is a parathyroid hormone (PTH) analog that has demonstrated
 increases in bone formation. ZT-031 is entering Phase 3 registration
 studies and has the potential to become a leading therapy to treat
 osteoporosis in the growing PTH market. In addition, Zelos
 Therapeutics is evaluating potential orthopedic uses of ZT-031's
 bone formation properties for fracture repair, trauma and use as a
 surgical adjunct.
Company: ZIOPHARM Oncology, Inc.
Ticker Symbol & Exchange: Nasdaq: ZIOP
Investor Relations Contact: Tyler Cook
Investor Relations Contact
 Phone: (617) 259-1982
Web: www.ziopharm.com
Date of Presentation: 11/11/2008
ZIOPHARM Oncology is a biopharmaceutical company engaged in the
 development and commercialization of a diverse portfolio of cancer
 drugs. The Company is currently focused on the development of three
 clinical programs for multiple indications. Palifosfamide (ZIO-201)
 is a novel molecule that is the functional active metabolite of
 ifosfamide, a standard of care for treating sarcoma, testicular
 cancer, lymphoma and other cancers. Indibulin (ZIO-301) is a novel,
 oral tubulin binding agent that targets both mitosis and cancer cell
 migration. Darinaparsin (ZIO-101) is a novel organic arsenic being
 developed for the treatment of various hematologic and solid
 cancers. For further information about ZIOPHARM visit
 www.ziopharm.com.

[ Back To TMCnet.com's Homepage ]